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  Neil	  A.	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  [The	  goal	  of	  this	  thesis	  is	  to	  examine	  the	  current	  state	  of	  prescription	  stimulant	  use,	  particularly	  on	  college	  campuses,	  and	  the	  impact	  of	  the	  attention-­‐deficit/hyperactivity	  disorder	  (ADHD)	  dilemma.	  	  I	  will	  first	  discuss	  the	  science	  explaining	  and	  relating	  ADHD	  etiology	  and	  the	  effects	  of	  stimulant	  medications	  on	  the	  mind	  and	  body.	  	  I	  will	  then	  discuss	  the	  accepted	  criteria	  for	  ADHD	  diagnosis	  and	  the	  ambiguity	  they	  create.	  	  Next	  I	  will	  identify	  the	  central	  issue:	  the	  widespread	  illicit	  use	  of	  stimulant	  medications,	  particularly	  for	  academic	  purposes.	  	  I	  will	  expound	  on	  the	  development	  of	  this	  situation,	  the	  influence	  of	  the	  competitive	  collegiate	  atmosphere,	  and	  the	  ethical	  questions	  that	  follow.	  	  Finally	  I	  will	  discuss	  alternate	  paradigms	  for	  the	  regulation	  of	  prescription	  stimulants,	  and	  I	  will	  conclude	  by	  proposing	  a	  potentially	  equitable	  solution	  derived	  from	  the	  Principlist	  system	  of	  ethics.]	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   INTRODUCTION	  	  	  	  	   Attention-­‐Deficit/Hyperactivity	  Disorder	  (ADHD)	  is	  an	  incredibly	  controversial	  topic.	  	  Debates	  regarding	  the	  legitimacy	  of	  this	  psychological	  condition	  have	  been	  raging	  for	  decades,	  and	  even	  so	  it	  seems	  today	  that	  we	  are	  still	  very	  far	  from	  any	  concrete	  resolution.	  	  Perhaps	  even	  more	  controversial	  is	  the	  use	  of	  stimulant	  medications	  for	  treating	  people	  with	  ADHD.	  	  Nearly	  eighty	  percent	  of	  all	  patients	  diagnosed	  with	  ADHD	  are	  prescribed	  one	  of	  a	  variety	  of	  drugs	  that	  have	  been	  shown	  to	  heighten	  attention	  and	  focus	  and	  increase	  memory	  efficiency	  [CDC,	  
2013].	  	  While	  some	  embrace	  these	  medications	  as	  miraculous	  and	  life	  changing,	  many	  are	  fearful	  of	  the	  consequences	  widespread,	  long-­‐term	  stimulant	  use	  may	  have	  for	  individual	  users	  and	  society	  as	  a	  whole.	  	  Even	  more	  alarming,	  a	  significant	  trend	  of	  illicit	  prescription	  stimulant	  use	  has	  emerged	  in	  recent	  years,	  most	  noticeably	  on	  college	  campuses.	  	  More	  and	  more	  students	  are	  discovering	  that	  stimulant	  medications	  can	  help	  them	  study	  longer	  and	  harder,	  and	  for	  many	  such	  advantages	  can	  be	  hard	  to	  turn	  down.	  	   The	  key	  questions	  are	  immediately	  apparent:	  	  Is	  ADHD	  a	  legitimate	  diagnosis?	  	  Are	  stimulants	  really	  a	  good	  form	  of	  treatment?	  	  Who	  deserves	  to	  benefit	  from	  stimulants	  and	  who	  doesn’t?	  	  How	  do	  we	  go	  about	  drawing	  the	  line	  for	  access	  to	  stimulants,	  and	  where	  do	  we	  draw	  it?	  	  I	  want	  to	  find	  the	  answers	  to	  these	  questions.	  	  The	  goal	  of	  this	  thesis	  is	  to	  tap	  into	  the	  discussion	  surrounding	  ADHD,	  
	   vii	  
prescription	  stimulants,	  and	  illicit	  stimulant	  use	  and	  to	  find	  an	  ethically	  sound	  approach	  for	  resolving	  this	  widely	  debated	  issue.	  	  I	  will	  first	  attempt	  to	  explain	  the	  complicated	  theoretical	  neuroscience	  behind	  the	  symptoms	  of	  ADHD	  and	  how	  stimulant	  medications	  work	  to	  attenuate	  these	  symptoms.	  	  I	  will	  then	  discuss	  the	  standards	  for	  ADHD	  diagnosis	  and	  address	  several	  of	  the	  issues	  that	  the	  current	  paradigm	  presents.	  	  These	  issues	  will	  be	  developed	  to	  explain	  the	  core	  problem	  of	  this	  discussion;	  that	  is,	  the	  widespread	  illicit	  use	  of	  prescription	  stimulants	  for	  personal	  benefit.	  	  I	  will	  then	  present	  different	  methods	  by	  which	  we	  might	  address	  this	  growing	  issue,	  weighing	  the	  pros	  and	  cons	  of	  each.	  	  Finally,	  I	  will	  attempt	  to	  formulate	  an	  ethically	  sound	  approach	  that	  reconciles	  certain	  conflicting	  principles	  and	  may	  help	  to	  provide	  the	  elusive	  resolution	  to	  this	  controversy.	  	  	  	  	  	  	  	  	  	  	  	  
	   1	  
	  	  	  	  
	  
CHAPTER	  	  I:	   THE	  HARD	  SCIENCE	  	  	   To	  gain	  a	  truly	  informed	  opinion	  on	  the	  subject	  at	  hand,	  one	  must	  understand	  the	  science	  behind	  it.	  	  This	  includes	  knowledge	  of	  the	  drugs	  themselves,	  their	  methods	  of	  action,	  and	  the	  potential	  risks	  associated	  with	  their	  use.	  	  Over	  the	  last	  half	  century,	  a	  suite	  of	  various	  pharmaceutical	  agents	  has	  been	  introduced	  for	  the	  treatment	  of	  ADHD.	  	  Today,	  the	  more	  commonly	  prescribed	  options	  are	  all	  classified	  as	  substituted	  phenethylamines.	  	  These	  include	  methylphenidate	  (Ritalin,	  Concerta),	  dexmethylphenidate	  (Focalin),	  dextroamphetamine	  (Dexedrine),	  lisdexamfetamine	  (Vyvanse),	  and	  a	  mixture	  of	  dextroamphetamine	  and	  amphetamine	  (Adderall)	  
[Spencer	  et	  al.,	  1998;	  WebMD,	  2015].	  	  	  	   Though	  the	  exact	  causes	  of	  ADHD	  are	  not	  absolutely	  known,	  the	  current	  theory	  promoted	  by	  most	  researchers	  suggests	  that	  the	  symptoms	  of	  this	  disorder	  are	  caused	  by	  functional	  impairment	  of	  certain	  neurotransmitter	  systems	  in	  the	  brain	  [Sulzer	  et	  al.,	  2005;	  Sydor	  &	  Brown,	  2008].	  	  The	  stimulant	  medications	  listed	  previously	  reduce	  the	  symptoms	  of	  ADHD	  by	  increasing	  activity	  in	  these	  systems.	  	  Specific	  actions	  include	  increased	  dopamine	  transmission	  in	  the	  nucleus	  accumbens	  in	  the	  mesocorticolimbic	  pathway	  and	  increased	  norepinephrine	  transmission	  in	  the	  locus	  coeruleus	  and	  the	  prefrontal	  cortex	  [Sulzer	  et	  al.,	  2005;	  
Sydor	  &	  Brown,	  2008].	  	  These	  neural	  pathways	  are	  associated	  with	  reward	  and	  memory	  processing.	  	  The	  flow	  of	  dopamine	  between	  neurons	  in	  these	  systems	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controls	  the	  rate	  at	  which	  information	  can	  be	  processed	  for	  memory	  formation,	  the	  level	  of	  reward	  associated	  with	  the	  information	  processing,	  and	  the	  level	  of	  motivation	  attached	  to	  this	  reward	  [Sydor	  &	  Brown,	  2008].	  	  The	  typical	  results	  are	  heightened	  pleasure	  response,	  increased	  motivation	  attached	  to	  relevant	  activities	  (i.e.	  heightened	  attention/focus),	  and	  enhanced	  memory	  processing.	  	  These	  effects	  are	  ideal	  for	  countering	  the	  symptoms	  of	  ADHD,	  and	  indeed	  more	  than	  70%	  of	  people	  diagnosed	  with	  ADHD	  show	  improvements	  in	  their	  symptoms	  when	  taking	  stimulant	  medications	  [CDC,	  2013].	  	  However,	  the	  actions	  of	  these	  drugs	  are	  not	  limited	  to	  those	  with	  ADHD.	  	  Virtually	  anyone	  will	  experience	  the	  same	  mental	  effects,	  provided	  that	  a	  conservative	  dosage	  is	  maintained.	  	   The	  side	  effects	  associated	  with	  stimulant	  use	  are	  many.	  	  At	  a	  normal	  pharmaceutical	  dosage,	  these	  effects	  are	  generally	  mild,	  however	  they	  become	  significantly	  more	  intense	  and	  dangerous	  as	  the	  dosage	  is	  increased	  [Sydor	  &	  
Brown,	  2008].	  	  The	  most	  pertinent	  effects	  are	  those	  on	  the	  cardiovascular	  system.	  	  Increased	  blood	  pressure	  (hypertension),	  increased	  heart	  rate	  (tachycardia),	  and	  reduced	  blood	  flow	  to	  the	  extremities	  (Raynaud’s	  phenomenon)	  are	  all	  associated	  with	  stimulant	  use	  [NIH,	  2015;	  Sydor	  &	  Brown,	  2008].	  	  Metabolic/gastrointestinal	  side	  effects	  include	  loss	  of	  appetite,	  nausea,	  increased	  motility,	  and	  weight	  loss.	  	  Respiration	  is	  increased,	  though	  at	  safe	  dosage	  levels	  this	  is	  generally	  not	  so	  significant	  as	  to	  be	  noticed.	  	  Also,	  people	  often	  experience	  dry	  mouth,	  teeth	  grinding,	  and	  mild	  tics	  when	  on	  stimulants	  [Sydor	  &	  Brown,	  2008].	  	  As	  previously	  stated,	  most	  of	  these	  effects	  are	  not	  particularly	  extreme,	  and	  at	  safe	  dosages	  they	  are	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experienced	  mildly.	  	  It	  is	  with	  heightened	  doses	  that	  the	  effects	  can	  become	  dangerous.	  	   All	  stimulant	  medications,	  particularly	  the	  amphetamine	  derivatives	  (Adderall,	  Vyvanse,	  Dexedrine),	  can	  be	  addictive	  [Arria	  et	  al.,	  2008;	  NIH,	  2015;	  
Spencer	  et	  al.,	  1998].	  	  When	  taken	  at	  a	  low	  recommended	  dosage,	  the	  risk	  for	  addiction	  development	  is	  extremely	  low	  [FDA,	  2007;	  Kollins,	  2008;	  Shulman,	  
2008].	  	  However,	  when	  used	  in	  excess,	  especially	  for	  recreational	  purposes,	  the	  risk	  for	  addiction	  development	  increases	  [Arria	  et	  al.,	  2008;	  Arria	  &	  DuPont,	  2010].	  	  The	  tolerance	  built	  up	  by	  addictive	  use	  leads	  to	  increased	  dosage,	  and	  this	  heightens	  the	  risk	  of	  overdosing.	  	  The	  symptoms	  of	  a	  stimulant	  overdose	  are	  essentially	  extreme	  side	  effect	  experiences.	  	  Extremely	  high	  heart	  rate	  and	  blood	  pressure	  are	  typical,	  and	  in	  some	  cases	  there	  may	  be	  an	  abnormal	  heartbeat.	  	  Confusion,	  severe	  agitation,	  rapid	  breathing,	  and	  muscular	  tremors	  are	  also	  common	  symptoms	  of	  overdose.	  	  A	  combination	  of	  all	  these	  effects	  is	  dangerous	  and	  can	  be	  physically	  detrimental,	  however,	  with	  appropriate	  medical	  care,	  stimulant	  overdoses	  are	  rarely	  fatal	  [Spiller	  et	  al.,	  2013].	  	   As	  explained	  previously,	  stimulant	  medications	  treat	  ADHD	  by	  stimulating	  activity	  in	  a	  specific	  suite	  of	  neurotransmitter	  systems.	  	  These	  systems	  are	  responsible	  for	  memory	  processing.	  	  For	  instance,	  when	  I	  work	  to	  write	  this	  thesis,	  these	  systems	  are	  actively	  working	  to	  encode	  the	  information	  I	  have	  read,	  the	  thoughts	  I	  have	  had,	  and	  the	  words	  I	  have	  typed	  into	  my	  functional	  memory,	  as	  well	  as	  the	  contextual	  information	  about	  where	  I	  was	  and	  how	  I	  was	  feeling	  when	  I	  performed	  this	  task.	  	  However,	  these	  systems	  don't	  just	  record	  these	  memories.	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They	  are	  also	  responsible	  for	  associating	  levels	  of	  reward	  with	  remembered	  actions.	  	  Activities	  associated	  with	  higher	  levels	  of	  reward	  are	  perceived	  as	  more	  exciting	  and	  desirable,	  and	  activities	  that	  are	  associated	  with	  lower	  levels	  of	  reward	  are	  perceived	  as	  uninteresting	  and	  avoidable.	  	  Finally,	  these	  neurotransmitter	  systems	  generate	  levels	  of	  motivation	  corresponding	  to	  the	  level	  of	  reward	  associated	  with	  certain	  actions.	  	  This	  motivation	  is	  generated	  to	  promote	  engagement	  in	  high	  reward	  activities	  by	  increasing	  focus	  and	  attentiveness,	  which	  leads	  to	  more	  efficient	  memory	  processing,	  which	  leads	  to	  more	  reward.	  	  This	  is	  how	  the	  system	  is	  meant	  to	  function.	  	  	  	   The	  activities	  that	  give	  us	  the	  greatest	  reward	  become	  the	  activities	  that	  we	  are	  most	  motivated	  to	  engage	  in.	  	  In	  the	  environment	  of	  human	  evolution,	  this	  brain	  process	  was	  key	  to	  survival.	  	  Hunting	  animals,	  building	  fire,	  and	  making	  love	  were	  all	  crucial	  to	  the	  survival	  of	  man,	  and	  in	  those	  harsh	  times	  performing	  these	  activities	  would	  have	  been	  associated	  with	  high	  levels	  of	  reward.	  	  This	  encoded	  perception	  of	  reward	  in	  turn,	  via	  specific	  neurotransmitter	  exchanges,	  generated	  levels	  of	  intensified	  motivation	  toward	  these	  activities,	  resulting	  in	  heightened	  focus	  and	  attentiveness	  for	  these	  tasks.	  	  Though	  our	  lives	  today	  are	  very	  different	  than	  the	  lives	  of	  our	  early	  ancestors,	  these	  neural	  pathways	  still	  function	  the	  same	  way	  in	  our	  brains.	  	  They	  form	  memories	  of	  activities,	  associate	  levels	  of	  reward	  with	  the	  activities,	  and	  generate	  motivation	  based	  on	  the	  levels	  of	  reward.	  	  This	  motivation	  leads	  to	  increased	  memory,	  increased	  reward,	  and	  increased	  motivation,	  thereby	  ensuring	  that	  the	  individual	  will	  continue	  to	  engage	  in	  these	  rewarding	  tasks.	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   According	  to	  the	  current	  biomedical	  model,	  a	  patient	  with	  ADHD	  suffers	  from	  impairment	  of	  these	  dopamine	  and	  norepinephrine	  systems	  [Sulzer	  et	  al.,	  2005;	  
Sydor	  &	  Brown,	  2008].	  	  Unless	  the	  patient	  experiences	  noticeable	  anhedonia	  (the	  inability	  to	  feel	  pleasure),	  it	  is	  likely	  that	  the	  problem	  lies	  with	  the	  generation	  of	  motivation.	  	  This	  would	  mean	  that	  the	  patient	  might	  find	  many	  activities	  perfectly	  rewarding	  but	  still	  would	  not	  experience	  any	  sustained	  internal	  motivation	  to	  engage	  in	  those	  activities.	  	  Because	  of	  this,	  the	  patient	  would	  not	  experience	  the	  attention	  and	  focus	  that	  come	  with	  motivation,	  and	  therefore	  would	  not	  benefit	  from	  the	  enhanced	  memory	  processing	  that	  comes	  with	  attention	  and	  focus.	  	  The	  unfortunate	  result	  for	  people	  with	  ADHD	  is	  that	  they	  find	  it	  impossible	  to	  keep	  their	  minds	  engaged	  on	  any	  one	  activity,	  no	  matter	  how	  rewarding	  it	  may	  be.	  	  This	  can	  be	  a	  truly	  debilitating	  condition,	  making	  information	  learning	  and	  skill	  development	  a	  constant	  struggle.	  	  Therapeutic	  doses	  of	  stimulant	  medications	  help	  to	  alleviate	  this	  struggle	  by	  increasing	  activity	  in	  these	  neurotransmitter	  systems	  and	  inducing	  motivation,	  attention,	  and	  focus.	  	   These	  stimulants	  do	  not	  only	  increase	  motivation,	  attention,	  and	  focus	  in	  people	  with	  ADHD,	  however.	  	  If	  we	  think	  about	  the	  underlying	  factors	  of	  this	  condition,	  this	  shouldn’t	  come	  as	  a	  surprise.	  	  ADHD	  is	  the	  result	  of	  abnormal	  variations	  in	  neurotransmitter	  activity.	  	  It’s	  not	  because	  a	  part	  of	  the	  brain	  is	  missing	  or	  deformed.	  	  It’s	  simply	  due	  to	  the	  fact	  that	  the	  person	  consistently	  has	  lower	  levels	  of	  dopamine	  and	  norepinephrine	  available	  in	  those	  areas	  of	  the	  brain,	  with	  the	  solution	  being	  to	  take	  a	  drug	  that	  increases	  those	  levels.	  	  The	  reality	  is	  that	  these	  drugs	  increase	  dopamine	  and	  norepinephrine	  activity	  within	  these	  systems	  in	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all	  brains,	  regardless	  of	  how	  “normal”	  they	  may	  be.	  	  As	  with	  every	  chemical	  in	  the	  body,	  there	  is	  a	  level	  for	  these	  neurotransmitters	  that	  is	  ideal	  for	  maximal	  motivation,	  attention,	  and	  focus.	  	  Lower	  levels	  lead	  to	  decreases	  in	  these	  functions,	  and	  higher	  levels	  lead	  to	  a	  sort	  of	  neural	  overload	  that	  can	  be	  functionally	  debilitating.	  	  In	  people	  with	  ADHD,	  these	  neurotransmitter	  levels	  are	  consistently	  low,	  and	  treatment	  with	  stimulant	  medications	  helps	  keep	  them	  at	  higher,	  more	  functional	  levels.	  	  In	  people	  who	  naturally	  have	  consistently	  high	  levels	  of	  these	  neurotransmitters,	  using	  stimulant	  medication	  often	  leads	  to	  excessive	  levels	  that	  hinder	  cognitive	  function.	  	  	  	   In	  more	  normal	  people,	  these	  neurotransmitter	  levels	  can	  vary	  for	  different	  activities.	  	  Activities	  that	  a	  person	  is	  more	  talented/proficient	  at	  and	  enjoys	  are	  associated	  with	  higher	  neurotransmitter	  levels,	  and	  activities	  that	  this	  person	  is	  less	  talented/proficient	  at	  and	  does	  not	  enjoy	  are	  associated	  with	  lower	  neurotransmitter	  levels.	  	  It	  is	  therefore	  possible	  for	  a	  person	  to	  use	  stimulant	  medications	  selectively	  to	  increase	  motivation,	  attention,	  and	  focus	  for	  activities	  that	  are	  perceived	  as	  less	  rewarding.	  	  This	  leads	  to	  increased	  memory	  processing	  and	  general	  productivity	  for	  these	  tasks,	  regardless	  of	  the	  perceived	  rewards.	  	  	  	   This	  might	  help	  to	  clarify	  why	  so	  many	  non-­‐ADHD	  students	  find	  using	  stimulants	  beneficial	  for	  academic	  performance.	  	  There	  are	  many	  people	  out	  there	  who	  do	  not	  enjoy	  school	  for	  any	  number	  of	  reasons,	  and	  this	  lack	  of	  neurotransmitter-­‐induced	  motivation	  tends	  to	  generate	  situation-­‐specific	  symptoms	  like	  those	  associated	  with	  ADHD.	  	  Stimulant	  medications	  can	  therefore	  help	  boost	  relevant	  neurotransmitter	  activity	  in	  these	  people	  when	  they	  are	  performing	  
	   7	  











CHAPTER	  	  II:	   THE	  DIAGNOSTIC	  PROCESS	  	   	  	   An	  abnormal	  psychological	  condition	  is	  best	  identified	  as	  a	  behavior	  or	  experience	  that:	  1)	  deviates	  from	  the	  societal	  norm,	  2)	  is	  somehow	  maladaptive,	  and	  3)	  causes	  the	  patient	  consistent/recurrent	  subjective	  distress	  (or	  sometimes	  instead	  causes	  collective	  third	  person	  distress)	  [Lyons	  &	  Martin,	  2011].	  	  Attention-­‐Deficit/Hyperactivity	  Disorder	  (ADHD)	  clearly	  meets	  each	  of	  these	  conditions.	  	  People	  with	  ADHD	  have	  an	  unusually	  low	  attentional	  capacity	  that	  hinders	  their	  ability	  to	  learn	  information	  and	  develop	  skills,	  which	  usually	  results	  in	  some	  subjective	  distress.	  	  However,	  ADHD	  is	  also	  an	  inherently	  ambiguous	  diagnosis.	  	  One	  does	  not	  need	  to	  discredit	  it	  as	  a	  legitimate	  condition	  in	  order	  to	  recognize	  this.	  	  As	  with	  most	  mental	  health	  disorders,	  there	  is	  no	  clear	  method	  that	  can	  indisputably	  identify	  ADHD	  in	  a	  patient.	  	  Rather,	  there	  is	  a	  swath	  of	  symptoms	  that,	  if	  enough	  of	  them	  are	  present	  simultaneously,	  legitimize	  a	  diagnosis	  of	  ADHD.	  	  The	  standard	  process	  for	  diagnosis,	  according	  to	  the	  Diagnostic	  and	  Statistical	  Manual,	  Fifth	  edition	  (DSM-­‐V),	  is	  fairly	  straightforward:	  	   People	  with	  ADHD	  show	  a	  persistent	  pattern	  of	  inattention	  and/or	  hyperactivity-­‐impulsivity	  that	  interferes	  with	  functioning	  or	  development:	  1. Inattention:	  Six	  or	  more	  symptoms	  of	  inattention	  for	  children	  up	  to	  age	  	   16,	  or	  five	  or	  more	  for	  adolescents	  17	  and	  older	  and	  adults;	  symptoms	  of	  
	   9	  
	   inattention	  have	  been	  present	  for	  at	  least	  6	  months,	  and	  they	  are	  	   inappropriate	  for	  developmental	  level:	  
o Often	  fails	  to	  give	  close	  attention	  to	  details	  or	  makes	  careless	  mistakes	  	   in	  schoolwork,	  at	  work,	  or	  with	  other	  activities.	  
o Often	  has	  trouble	  holding	  attention	  on	  tasks	  or	  play	  activities.	  
o Often	  does	  not	  seem	  to	  listen	  when	  spoken	  to	  directly.	  
o Often	  does	  not	  follow	  through	  on	  instructions	  and	  fails	  to	  finish	  	   schoolwork,	  chores,	  or	  duties	  in	  the	  workplace	  (e.g.,	  loses	  	   focus,	  side-­‐tracked).	  
o Often	  has	  trouble	  organizing	  tasks	  and	  activities.	  
o Often	  avoids,	  dislikes,	  or	  is	  reluctant	  to	  do	  tasks	  that	  require	  mental	  	   effort	  over	  a	  long	  period	  of	  time	  (such	  as	  schoolwork	  or	  	   homework).	  
o Often	  loses	  things	  necessary	  for	  tasks	  and	  activities	  (e.g.	  school	  	   materials,	  pencils,	  books,	  tools,	  wallets,	  keys,	  paperwork,	  	   eyeglasses,	  mobile	  telephones).	  
o Is	  often	  easily	  distracted.	  
o Is	  often	  forgetful	  in	  daily	  activities.	  2. Hyperactivity	  and	  Impulsivity:	  Six	  or	  more	  symptoms	  of	  hyperactivity-­‐	   impulsivity	  for	  children	  up	  to	  age	  16,	  or	  five	  or	  more	  for	  adolescents	  17	  	   and	  older	  and	  adults;	  symptoms	  of	  hyperactivity-­‐impulsivity	  have	  been	  	   present	  for	  at	  least	  6	  months	  to	  an	  extent	  that	  is	  disruptive	  and	  	   inappropriate	  for	  the	  person’s	  developmental	  level:	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o Often	  fidgets	  with	  or	  taps	  hands	  or	  feet,	  or	  squirms	  in	  seat.	  
o Often	  leaves	  seat	  in	  situations	  when	  remaining	  seated	  is	  expected.	  
o Often	  runs	  about	  or	  climbs	  in	  situations	  where	  it	  is	  not	  appropriate	  (adolescents	  or	  adults	  may	  be	  limited	  to	  feeling	  restless).	  
o Often	  unable	  to	  play	  or	  take	  part	  in	  leisure	  activities	  quietly.	  
o Is	  often	  "on	  the	  go"	  acting	  as	  if	  "driven	  by	  a	  motor".	  
o Often	  talks	  excessively.	  
o Often	  blurts	  out	  an	  answer	  before	  a	  question	  has	  been	  completed.	  
o Often	  has	  trouble	  waiting	  his/her	  turn.	  
o Often	  interrupts	  or	  intrudes	  on	  others	  (e.g.,	  butts	  into	  	   conversations	  or	  games)	  3.	   In	  addition,	  the	  following	  conditions	  must	  be	  met:	  
o Several	  inattentive	  or	  hyperactive-­‐impulsive	  symptoms	  were	  present	  before	  age	  12	  years.	  
o Several	  symptoms	  are	  present	  in	  two	  or	  more	  settings,	  (e.g.,	  at	  home,	  	   school	  or	  work;	  with	  friends	  or	  relatives;	  in	  other	  activities).	  
o There	  is	  clear	  evidence	  that	  the	  symptoms	  interfere	  with,	  or	  reduce	  the	  quality	  of,	  social,	  school,	  or	  work	  functioning.	  
o The	  symptoms	  do	  not	  happen	  only	  during	  the	  course	  of	  schizophrenia	  or	  another	  psychotic	  disorder.	  	  The	  symptoms	  are	  not	  better	  explained	  by	  another	  mental	  disorder	  (e.g.	  Mood	  Disorder,	  Anxiety	  Disorder,	  Dissociative	  Disorder,	  or	  a	  Personality	  Disorder).	  	  	   	   	   	   	   	   	   	   	   [DSM-­‐V,	  2013]	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   This	  wide	  range	  of	  criteria	  for	  diagnosis	  is	  a	  testament	  to	  this	  disorder’s	  inherent	  ambiguity.	  	  In	  fact,	  it	  is	  entirely	  possible	  for	  two	  people	  to	  be	  diagnosed	  with	  ADHD	  while	  only	  displaying	  two	  common	  symptoms	  (each	  must	  present	  with	  5	  out	  of	  9	  for	  each	  symptom	  grouping).	  	  If	  nothing	  else,	  this	  illustrates	  how	  ADHD	  exists	  on	  a	  spectrum	  (as	  do	  most	  mental	  health	  disorders).	  	  Not	  only	  can	  the	  types	  of	  symptoms	  vary,	  but	  the	  extremity	  of	  each	  symptomatic	  experience	  can	  vary	  as	  well.	  	  With	  so	  much	  variation	  in	  the	  criteria	  for	  diagnosis,	  the	  qualifying	  line	  becomes	  extremely	  blurry.	  	  What	  if	  an	  adult	  patient	  presents	  with	  four	  of	  each	  symptom	  group,	  and	  his	  symptoms	  are	  fairly	  extreme?	  	  How	  does	  he	  compare	  to	  an	  adult	  patient	  that	  presents	  with	  five	  of	  each	  symptom	  group	  and	  experiences	  them	  only	  to	  a	  mild	  (albeit	  noticeable)	  degree?	  	  Is	  the	  patient	  with	  fewer	  symptoms	  truly	  less	  deserving	  of	  therapeutic	  intervention?	  	  	   One	  of	  the	  most	  ambiguous	  and	  troubling	  criteria	  is	  that	  “several”	  symptoms	  must	  be	  present	  in	  “two	  or	  more”	  settings.	  	  How	  many	  symptoms	  are	  “several”?	  	  Four?	  	  Five?	  	  Six?	  	  If	  a	  person	  were	  truly	  suffering	  from	  ADHD,	  then	  wouldn't	  it	  be	  reasonable	  to	  expect	  him	  to	  display	  virtually	  all	  of	  his	  symptoms	  across	  all	  environments?	  	  When	  considering	  the	  biological	  factors	  involved	  in	  ADHD,	  it	  is	  important	  to	  remember	  that	  most	  people	  are	  likely	  to	  be	  inattentive	  and	  restless	  in	  at	  least	  some	  scenarios.	  	  The	  majority	  of	  us	  experience	  a	  variety	  of	  attentional	  dispositions—we	  feel	  motivated	  to	  engage	  in	  certain	  activities	  and	  discouraged	  from	  engaging	  in	  others.	  	  This	  is	  of	  course	  very	  normal,	  however	  many	  have	  become	  convinced	  that	  a	  lack	  of	  motivation	  for	  some	  certain	  activities	  qualifies	  as	  ADHD.	  	  It	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has	  become	  common	  for	  people	  to	  claim	  “I	  have	  school	  ADD”	  or	  “I’m	  only	  ADD	  when	  I	  try	  to	  read”.	  	  Although	  difficulty	  reading	  and	  completing	  schoolwork	  are	  the	  hallmark	  deficits	  associated	  with	  ADHD,	  they	  are	  certainly	  not	  enough	  alone	  to	  qualify	  for	  diagnosis.	  	  	  	   Let’s	  consider	  an	  example.	  	  You	  meet	  a	  person	  who	  hates	  school	  and	  struggles	  to	  complete	  his	  classwork.	  	  He	  has	  a	  hard	  time	  paying	  attention	  in	  class	  and	  usually	  just	  daydreams.	  	  However,	  when	  he	  gets	  home,	  he	  spends	  hours	  every	  day	  playing	  the	  guitar,	  immersed	  in	  his	  instrument.	  	  He	  occasionally	  writes	  music	  and	  lyrics.	  	  His	  parents	  are	  frustrated	  with	  his	  academic	  performance,	  and	  every	  time	  they	  confront	  him,	  he	  explains	  that	  he	  just	  can’t	  focus	  at	  school.	  	  Does	  this	  person	  qualify	  for	  an	  ADHD	  diagnosis?	  	  His	  parents	  probably	  think	  so,	  but	  what	  does	  the	  evidence	  say?	  	  He	  clearly	  has	  problems	  with	  attentiveness	  when	  school	  is	  involved,	  however	  when	  he	  is	  making	  music	  he	  is	  completely	  zoned	  in.	  	  For	  this	  reason,	  I	  would	  argue	  that	  he	  does	  not	  suffer	  from	  ADHD.	  	  He	  is	  perfectly	  capable	  of	  focusing	  in	  certain	  situations,	  even	  if	  school	  isn’t	  one	  of	  them.	  	  But	  his	  parents	  and	  teachers	  aren’t	  happy	  with	  this	  diagnosis.	  	  Why?	  	  Because	  he	  is	  clearly	  “ADHD”	  at	  school.	  	  And	  unfortunately	  it	  seems	  that,	  to	  many	  diagnosticians,	  this	  is	  all	  that	  really	  matters.	  	  If	  a	  student	  is	  falling	  short	  in	  school,	  and	  he	  meets	  a	  satisfactory	  amount	  of	  the	  criteria	  listed	  previously,	  then	  there	  is	  a	  very	  good	  chance	  this	  student	  will	  be	  diagnosed	  with	  ADHD,	  even	  if	  he	  really	  only	  shows	  symptoms	  when	  school	  is	  involved.	  	  Part	  of	  this	  seems	  to	  be	  derived	  from	  the	  utmost	  importance	  we	  place	  on	  academic	  success.	  	  We	  view	  slipping	  academic	  performance	  as	  the	  worst	  affliction	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associated	  with	  ADHD,	  but	  the	  reality	  is	  that	  people	  with	  true	  ADHD	  suffer	  in	  much	  broader	  terms.	  	  	  	  	   Ultimately,	  diagnosis	  is	  left	  up	  to	  the	  informed	  judgment	  of	  our	  mental	  health	  professionals	  (psychologists	  and	  psychiatrists).	  	  These	  clinicians	  observe,	  interview,	  and	  test	  their	  patients	  using	  standard	  methods	  and,	  with	  the	  DSM-­‐V	  as	  a	  guide,	  determine	  whether	  they	  believe	  their	  patients	  qualify	  for	  ADHD	  diagnoses.	  	  Depending	  on	  the	  diagnostician,	  this	  process	  can	  be	  quick	  and	  easy	  or	  long	  and	  arduous.	  	  It	  can	  take	  hours	  or	  it	  can	  take	  weeks.	  	  Once	  a	  diagnosis	  has	  been	  made,	  they	  move	  to	  the	  next	  step…	  treatment.	  	  	  	   It	  will	  come	  as	  no	  surprise	  to	  any	  reader	  that	  stimulant	  medication	  is	  by	  far	  the	  most	  common	  form	  of	  treatment	  for	  ADHD,	  with	  up	  to	  80%	  of	  people	  diagnosed	  with	  ADHD	  receiving	  prescriptions	  [CDC,	  2013].	  	  This	  is	  not	  necessarily	  without	  reason;	  the	  medications	  do	  seem	  to	  work.	  	  However,	  stimulant	  medication	  is	  not	  the	  only	  treatment	  method	  to	  demonstrate	  effectiveness.	  	  Studies	  have	  shown	  that	  cognitive-­‐behavioral	  therapy	  (CBT),	  meditation,	  and	  exercise	  can	  be	  effective	  in	  attenuating	  the	  symptoms	  of	  ADHD	  [Lyons	  &	  Martin,	  2011].	  	  However,	  these	  treatment	  methods	  require	  regular	  clinician	  visits,	  which	  require	  additional	  time	  and	  money.	  	  It	  is	  often	  very	  difficult	  for	  clinicians	  to	  get	  their	  patients	  back	  in	  for	  multiple/regular	  visits,	  and	  most	  patients	  would	  prefer	  not	  to	  foot	  the	  bill	  for	  repetitive	  doctor	  visits.	  	  Not	  only	  that,	  but	  every	  non-­‐pharmaceutical	  method	  of	  ADHD	  treatment	  requires	  extensive	  compliance	  on	  the	  part	  of	  the	  patient.	  	  They	  must	  buy	  into	  the	  therapy,	  and	  they	  must	  have	  the	  discipline	  to	  stick	  with	  it	  for	  an	  extended	  period	  of	  time.	  	  This	  is	  often	  more	  than	  can	  be	  expected	  from	  most	  modern	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patients.	  	  Overall,	  stimulant	  medication	  is	  usually	  the	  cheaper	  and	  more	  convenient	  option,	  and	  therefore	  by	  far	  the	  most	  popular	  choice.	  	  	  	   Since	  1990,	  diagnosis	  of	  Attention-­‐Deficit/Hyperactivity	  Disorder	  (ADHD)	  in	  children	  and	  young	  adults	  in	  the	  United	  States	  has	  quintupled,	  up	  to	  nearly	  10%	  of	  the	  population	  ages	  7	  to	  25	  in	  2013	  [CDC,	  2013].	  	  Approximately	  80%	  of	  these	  patients	  are	  or	  have	  been	  treated	  with	  stimulant	  medications	  [CDC,	  2013].	  	  Today,	  the	  U.S.	  contains	  4%	  of	  the	  world’s	  population,	  yet	  this	  4%	  consumes	  around	  70%	  of	  the	  world’s	  supply	  of	  stimulant	  medications	  [CDC,	  2013].	  	  These	  are	  some	  of	  the	  broadest	  statistics	  that	  shed	  light	  on	  the	  state	  of	  ADHD/stimulant	  affairs	  in	  this	  country.	  	  The	  rate	  of	  ADHD	  diagnosis	  in	  the	  U.S.	  dwarfs	  that	  of	  any	  other	  country.	  	  The	  rate	  of	  stimulant	  prescription	  for	  the	  treatment	  of	  ADHD	  in	  the	  U.S.	  dwarfs	  the	  others	  still	  further.	  	  	  	   These	  statistics	  are	  alarming	  and	  logically	  imply	  that	  something	  is	  up.	  	  The	  general	  consensus	  from	  the	  professional	  community	  seems	  to	  be	  that	  1)	  ADHD	  is	  over-­‐diagnosed,	  and	  2)	  stimulant	  medications	  are	  over-­‐prescribed	  [Arria	  &	  
DuPont,	  2010].	  	  The	  first	  contention	  is	  a	  testament	  to	  the	  ambiguous	  and	  arbitrary	  nature	  of	  the	  diagnostic	  process.	  	  The	  guidelines	  put	  forth	  in	  the	  DSM-­‐V	  are	  both	  broad	  and	  loose,	  and	  as	  a	  result	  it	  is	  easy	  for	  clinicians	  to	  bend	  the	  criteria	  to	  fit	  the	  wide	  variety	  of	  patients	  that	  come	  through	  their	  doors.	  	  	  	   The	  case	  of	  the	  college	  student	  is	  particularly	  problematic.	  	  Young	  children	  are	  less	  conscious	  of	  their	  behavior	  and	  completely	  unaware	  of	  what	  it	  takes	  to	  be	  diagnosed	  with	  ADHD.	  	  College	  students,	  on	  the	  other	  hand,	  are	  much	  more	  conscious	  of	  their	  own	  behaviors	  and	  know	  very	  well	  what	  it	  takes	  to	  receive	  a	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diagnosis.	  	  This	  makes	  the	  job	  of	  diagnosticians	  doubly	  challenging.	  	  On	  the	  one	  hand	  they	  must	  take	  into	  account	  that	  adolescent	  patients	  may	  unknowingly	  mask	  some	  of	  the	  underlying	  symptoms	  of	  ADHD,	  and	  on	  the	  other	  they	  must	  be	  wary	  of	  those	  patients	  that	  know	  exactly	  the	  behavior	  they	  need	  to	  exhibit	  to	  elicit	  a	  prescription.	  	  And	  when	  the	  parents	  of	  those	  students	  advocate	  for	  diagnosis	  and	  prescription,	  that	  only	  adds	  to	  the	  pressure.	  	  With	  so	  much	  ambiguity	  in	  the	  general	  criteria,	  it	  doesn’t	  seem	  a	  stretch	  to	  assume	  that	  diagnosticians	  look	  to	  academic	  performance	  as	  the	  most	  functional	  indicator	  of	  the	  symptoms.	  	  Consider	  this	  mock	  diagnosis	  for	  an	  18-­‐year-­‐old	  male	  patient:	  	   Does	  the	  student	  report	  struggling	  to	  concentrate?	  	  Yes.	  
	   Does	  the	  student	  have	  trouble	  reading	  for	  extended	  periods	  of	  time?	  	  Yes.	  	  	   Is	  the	  student	  frustrated	  with	  his	  grades?	  	  Yes.	  	   How	  much	  time	  does	  the	  student	  spend	  studying?	  	  Makes	  periodic	  	   	  
	   attempts	  to	  seriously	  study	  but	  always	  gets	  frustrated	  and	  quits	  	   	  
	   early.	  	  	   Does	  the	  student	  think	  he	  is	  capable	  of	  more?	  	  Yes,	  confidently.	  
	   Does	  the	  student	  appear	  and	  report	  being	  distressed?	  	  Yes	  and	  Yes.	  	   Do	  the	  student’s	  parents	  give	  corroborating	  observations?	  	  Yes,	  they	  say	  	  
	   he	  has	  always	  been	  this	  way	  but	  they	  were	  reluctant	  to	  have	  him	  	  	  
	   diagnosed,	  however	  they	  are	  now	  worried	  that	  his	  future	  may	  be	  in	  	  
	   jeopardy	  and	  want	  him	  to	  receive	  help.	  	   Do	  standard	  tests	  suggest	  the	  student	  has	  an	  attentional	  deficit?	  	  Yes,	  they	  	  
	   show	  his	  performance	  for	  attention-­‐intensive	  tasks	  is	  below	  normal.	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This	  has	  the	  makings	  of	  an	  accurate	  diagnosis,	  but	  it	  is	  lacking	  two	  major	  features.	  	  The	  challenge	  becomes	  deciding	  how	  to	  interpret	  the	  more	  ambiguous	  criteria:	  	   Does	  the	  student	  show	  symptoms	  of	  hyperactivity	  and	  impulsivity?	  	  	   	  	   Possibly...	  however,	  people	  with	  ADHD	  often	  grow	  out	  of	  these	  types	  	  
	   of	  symptoms	  as	  they	  mature	  into	  young	  adults	  since	  they	  are	  more	  	  
	   noticeable	  and	  directly	  repressible.	  	   Does	  the	  student	  show	  multiple	  symptoms	  in	  multiple	  settings?	  	  Maybe…	  	  
	   however,	  people	  his	  age	  often	  learn	  to	  mask	  their	  symptoms	  in	  many	  	  
	   settings,	  academic	  performance	  is	  often	  the	  only	  reliable	  indicator	  of	  	  
	   functional	  deficit.	  
	   Does	  the	  student	  qualify	  for	  another	  mental	  disorder	  that	  might	  better	  	   explain	  his	  symptoms?	  	  The	  student	  and	  his	  parents	  are	  adamant	  that	  his	  	  
	   attentional	  deficit	  is	  the	  ultimate	  source	  of	  his	  distress;	  any	  	   	  
	   comorbid	  anxiety	  or	  depression	  could	  result	  from	  the	  academic	  	   	  
	   struggles	  associated	  with	  ADHD.	  	   Should	  this	  student	  be	  diagnosed	  with	  ADHD?	  	  At	  this	  point	  it	  is	  hard	  to	  be	  sure.	  	  He	  definitely	  has	  trouble	  concentrating,	  but	  we	  aren’t	  sure	  how	  broadly	  he	  experiences	  these	  symptoms.	  	  The	  conditions	  he	  may	  not	  fully	  meet	  are	  the	  most	  ambiguous,	  and	  there	  may	  be	  no	  way	  to	  know	  for	  sure	  whether	  they	  apply	  to	  him.	  	  It’s	  also	  possible	  that	  his	  symptoms	  may	  actually	  be	  linked	  to	  another	  mental	  disorder,	  though	  it	  would	  require	  additional	  sessions	  and	  tests	  to	  be	  more	  certain,	  and	  even	  then	  it’s	  still	  likely	  he	  best	  fits	  the	  ADHD	  criteria.	  	  His	  symptoms	  fit	  the	  description,	  there	  aren’t	  any	  major	  red	  flags,	  and	  further	  testing	  is	  costly	  and	  will	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likely	  still	  support	  the	  original	  hunch.	  	  These	  conditions	  are	  usually	  enough	  for	  many	  (if	  not	  most)	  clinicians	  to	  render	  an	  ADHD	  diagnosis,	  so	  we	  will	  follow	  suit	  with	  our	  mock	  student.	  	  	  	   We	  have	  now	  decided	  that	  he	  does	  indeed	  have	  ADHD.	  	  Now	  we	  have	  to	  decide	  how	  to	  treat	  him.	  	  Luckily,	  our	  initial	  session	  provided	  us	  with	  some	  more	  pertinent	  information.	  	  His	  parents	  say	  that	  money	  is	  tight,	  meaning	  they	  would	  struggle	  to	  pay	  for	  additional	  regular	  sessions.	  	  He	  is	  enrolled	  with	  a	  full	  course-­‐load	  at	  a	  university	  four	  hours	  away,	  making	  scheduling	  future	  sessions	  required	  for	  extended	  CBT	  very	  difficult.	  	  This	  information	  is	  almost	  certainly	  enough	  to	  discourage	  most	  clinicians	  from	  pursuing	  non-­‐pharmaceutical	  approaches,	  so	  prescribed	  stimulant	  medication	  it	  is.	  	  	  	   This	  example	  goes	  to	  show	  how	  difficult	  making	  an	  accurate	  ADHD	  diagnosis	  can	  be,	  especially	  with	  a	  college	  student.	  	  Could	  the	  student	  be	  exaggerating	  his	  struggles?	  	  Yes.	  	  Could	  the	  student	  just	  be	  a	  lazy	  bum	  that	  tricked	  his	  parents	  into	  helping	  him	  solicit	  an	  Adderall	  prescription?	  	  It	  is	  possible.	  	  Could	  the	  student	  in	  truth	  fall	  short	  of	  the	  criteria	  for	  diagnosis?	  	  Maybe	  so,	  but	  with	  so	  much	  ambiguity	  why	  risk	  not	  helping	  him	  at	  all?	  	  If	  he	  really	  does	  have	  ADHD	  then	  this	  prescription	  might	  drastically	  improve	  his	  life.	  	  If	  he	  doesn’t	  really	  have	  ADHD,	  he	  might	  still	  derive	  some	  benefit	  from	  occasional	  stimulant	  use.	  	  Research	  suggests	  the	  medication	  is	  harmless	  enough	  at	  prescribed	  doses,	  so	  how	  bad	  could	  a	  close-­‐but-­‐false	  positive	  be?	  	  Better	  that	  than	  let	  him	  be	  a	  false	  negative	  and	  continue	  to	  suffer	  without	  treatment.	  	  All	  things	  considered,	  this	  appears	  to	  be	  the	  best	  course	  of	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action	  for	  this	  patient.	  	  And	  it’s	  not	  like	  this	  could	  negatively	  affect	  anyone	  else,	  right?	  	  [To	  be	  addressed	  in	  Chapter	  III]	  	   Another	  major	  problem	  with	  the	  prescription	  of	  stimulant	  medications	  is	  that	  there	  is	  no	  way	  to	  quantifiably	  measure	  their	  efficacy.	  	  Given	  the	  three	  conditions	  that	  define	  an	  abnormal	  behavior	  or	  experience—1)	  deviates	  from	  societal	  norms,	  2)	  is	  maladaptive,	  3)	  causes	  subjective	  distress—the	  ultimate	  goal	  of	  any	  treatment	  method	  should	  be	  to	  relieve	  distress	  by	  returning	  the	  patient	  to	  a	  normal,	  adequate	  functional	  state.	  	  Stimulant	  medication	  therapy	  for	  ADHD	  is	  no	  exception.	  	  To	  evaluate	  this	  treatment	  method,	  we	  must	  first	  ask:	  Does	  it	  relieve	  distress?	  	  Decades	  of	  observation	  and	  ever-­‐increasing	  prescription	  rates	  clearly	  suggest	  that	  patients	  are	  getting	  the	  results	  they	  want,	  so	  that	  seems	  to	  be	  a	  definitive	  yes.	  	  	  	   Next	  we	  must	  ask:	  Is	  the	  therapy	  restoring	  patients	  to	  a	  normal	  level	  of	  functioning?	  	  Simply	  relieving	  distress	  does	  not	  guarantee	  normal	  functioning.	  	  For	  instance,	  alcohol	  can	  provide	  relief	  from	  distress	  associated	  with	  anxiety,	  but	  it	  certainly	  does	  not	  restore	  normal	  functioning.	  	  But	  how	  are	  we	  to	  define	  a	  “normal”	  level	  of	  mental	  functioning?	  	  With	  most	  medical	  conditions,	  it	  is	  clear	  what	  “normal”	  is—a	  blood	  pressure	  of	  approximately	  120/80,	  a	  body	  temperature	  of	  98°,	  a	  perfectly	  straight	  femur,	  etc.	  	  However,	  if	  someone	  suffering	  from	  ADHD	  experiences	  functional	  deficits,	  how	  are	  we	  to	  determine	  what	  degree	  of	  stimulant	  treatment	  restores	  him/her	  to	  that	  ideal	  “normal”	  level?	  	  If	  we	  define	  “normal”	  as	  the	  typical	  or	  average	  state	  of	  conditions	  for	  that	  person,	  then	  determining	  a	  “normal”	  level	  of	  functioning	  beyond	  baseline	  for	  an	  individual	  with	  ADHD	  is	  necessarily	  impossible.	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In	  fact,	  one	  could	  argue	  that	  an	  inhibited	  functional	  level	  is	  “normal”	  for	  those	  with	  ADHD.	  	  	  	   Ultimately,	  the	  measure	  of	  efficacy	  for	  these	  medications	  is	  not	  analysis	  of	  neurochemical	  balance	  or	  brain	  activity,	  but	  satisfactory	  academic	  performance.	  	  So	  how	  are	  we	  to	  determine	  what	  a	  satisfactory	  goal	  [acceptable	  “norm”]	  for	  treatment	  is	  for	  an	  individual	  in	  a	  given	  population	  when	  capacities	  for	  attention,	  memory,	  and	  general	  intelligence	  vary	  inherently	  from	  person	  to	  person?	  	  Are	  As	  normal?	  	  Certainly	  not.	  	  That’s	  why	  they	  are	  prized.	  	  What	  about	  Bs,	  or	  Cs,	  or	  Ds	  ?	  	  The	  point	  is	  that	  there	  is	  no	  real	  medical	  standard	  for	  efficacy	  of	  stimulant	  medication	  therapy	  in	  college	  students	  outside	  of	  individual	  patient	  satisfaction	  with	  his/her	  academic	  performance.	  	  If	  a	  patient	  is	  still	  unhappy	  with	  his/her	  level	  of	  performance,	  then	  they	  are	  likely	  to	  receive	  an	  increased	  dosage.	  	  Once	  a	  patient	  is	  satisfied	  with	  his/her	  performance,	  there	  is	  no	  need	  to	  change	  the	  dosage.	  	  The	  medicine	  is	  clearly	  working.	  	  In	  this	  light,	  it	  appears	  that	  these	  stimulants	  don’t	  simply	  restore	  the	  patient	  to	  a	  normal	  level	  of	  functioning,	  but	  rather	  enhance	  the	  patient	  to	  his/her	  
desired	  level	  of	  functioning.	  	  If	  this	  is	  the	  case,	  then	  isn’t	  it	  more	  accurate	  and	  honest	  to	  describe	  stimulant	  medication	  as	  enhancement	  therapy?	  	  	  	   If	  this	  discussion	  of	  ADHD	  diagnosis	  and	  treatment	  has	  shown	  us	  anything,	  it	  is	  that	  the	  waters	  are	  murky…	  very	  murky.	  	  We	  see	  now	  that	  the	  criteria	  for	  diagnosis,	  as	  laid	  down	  in	  the	  DSM-­‐V,	  are	  broad	  and	  very	  ambiguous.	  	  Though	  it	  is	  specific	  about	  which	  behavior	  characteristics	  may	  be	  indicative	  of	  ADHD,	  only	  a	  certain	  number	  are	  required	  to	  justify	  diagnosis.	  	  This	  allows	  for	  a	  wide	  variety	  of	  behavior	  combinations	  that	  supposedly	  qualify	  one	  as	  having	  ADHD.	  	  The	  DSM-­‐V	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CHAPTER	  	  III:	   THE	  VISIBLE	  ISSUE	  	  	   So	  what’s	  the	  problem	  with	  stimulant	  medications?	  	  Why	  should	  we	  care?	  The	  reality	  is	  that	  students	  certifiably	  diagnosed	  with	  ADHD	  are	  not	  the	  only	  ones	  using	  these	  medications	  to	  get	  schoolwork	  done.	  	  Numerous	  studies	  have	  shown	  that	  illicit	  stimulant	  use	  (i.e.	  use	  by	  people	  without	  stimulant	  prescriptions)	  is	  a	  very	  real	  issue	  on	  America’s	  college	  campuses,	  and	  recent	  research	  has	  shown	  that	  those	  rates	  continue	  to	  grow	  every	  year	  [Arria	  &	  DuPont,	  2010;	  DeSantis	  et	  al.,	  2008;	  
McCabe	  et	  al.,	  2005].	  	  Studies	  have	  estimated	  the	  number	  of	  non-­‐prescribed	  college	  students	  who	  use	  stimulants	  to	  be	  anywhere	  from	  17%	  to	  34%,	  and	  that	  the	  vast	  majority	  of	  these	  use	  the	  medications	  for	  academic	  reason	  (e.g.	  reading,	  homework,	  and	  the	  ever-­‐popular	  late-­‐night	  cramming	  for	  exams)	  [Arria	  &	  DuPont,	  2010;	  
DeSantis	  et	  al.,	  2008;	  Garnier	  et	  al.,	  2010].	  	  The	  key	  reasons	  for	  the	  widespread	  use	  of	  these	  medications	  are:	  1)	  they	  are	  relatively	  easy	  to	  obtain,	  2)	  their	  effects	  are	  perceived	  as	  being	  acute	  and	  temporary,	  and	  3)	  they	  are	  widely	  reputed	  to	  be	  performance	  enhancers.	  	   Research	  continues	  to	  show	  that	  stimulant	  medications	  are	  becoming	  increasingly	  easy	  to	  obtain.	  	  Studies	  have	  shown	  that	  between	  55%	  and	  82%	  of	  students,	  including	  stimulant	  users	  and	  non-­‐users,	  believe	  that	  it	  is	  somewhat	  or	  very	  easy	  to	  obtain	  stimulant	  medication	  [DeSantis	  et	  al.,	  2008;	  Sharp	  &	  Rosén,	  
2007].	  	  Between	  68%	  and	  91%	  of	  stimulant	  users	  reported	  that	  they	  obtained	  them	  
	   22	  
from	  peers	  (friends	  or	  significant	  others)	  with	  prescriptions	  [DeSantis	  et	  al.,	  2008;	  
McCabe	  et	  al.,	  2005].	  	  Other	  studies	  on	  stimulant	  distributors	  have	  shown	  that	  between	  53%	  and	  62%	  of	  students	  with	  stimulant	  prescriptions	  admit	  to	  having	  either	  sold	  or	  given	  away	  some	  of	  their	  supply	  to	  students	  without	  prescriptions	  
[DeSantis	  et	  al.,	  2013;	  Garnier	  et	  al.,	  2010].	  	  	  	   A	  comprehensive	  review	  of	  the	  literature	  clearly	  shows	  three	  important	  things:	  1)	  that	  the	  majority	  of	  stimulant	  prescription	  holders	  do	  not	  mind	  diverting	  their	  drugs	  to	  non-­‐prescribed	  students,	  2)	  that	  the	  majority	  of	  illicit	  stimulant	  users	  get	  their	  supply	  from	  peers	  with	  prescriptions,	  and	  3)	  that	  the	  overwhelming	  majority	  of	  students,	  users	  and	  nonusers,	  prescribed	  and	  non-­‐prescribed,	  believe	  that	  illicitly	  obtaining	  stimulant	  medications	  is	  fairly	  easy.	  	  If	  one	  feels	  the	  “need”	  to	  take	  stimulants	  in	  order	  to	  study,	  getting	  them	  is	  clearly	  not	  very	  hard.	  	  	   Here	  are	  some	  informal	  examples	  to	  help	  illustrate	  the	  ease	  with	  which	  stimulants	  can	  be	  acquired.	  	  For	  contrast,	  if	  one	  asks	  the	  right	  guy	  where	  to	  get	  some	  marijuana,	  if	  he	  is	  in	  the	  know	  then	  he	  will	  likely	  give	  the	  name	  of	  a	  specific	  person	  who	  is	  purposefully	  known	  for	  distributing	  marijuana,	  and	  one	  generally	  has	  to	  ask	  around	  a	  bit	  before	  finally	  being	  referenced	  to	  such	  a	  person.	  	  Responses	  are	  generally	  along	  the	  lines	  of,	  “Yeah,	  ______	  has	  been	  selling.	  	  I’ll	  see	  if	  he	  has	  any,”	  or	  the	  more	  secretive,	  “Yeah	  I	  know	  a	  guy.	  	  You	  want	  me	  to	  get	  you	  some?”	  	  However,	  with	  stimulant	  medications	  it	  is	  very	  different.	  	  Almost	  anyone	  one	  asks	  will	  know	  where	  to	  get	  a	  hold	  of	  some,	  and	  the	  tips	  are	  usually	  not	  as	  specific	  or	  secretive	  as	  might	  be	  expected.	  	  Responses	  are	  usually	  along	  the	  lines	  of,	  “Yeah	  I	  think	  ______	  has	  a	  prescription.	  	  I’m	  sure	  he’ll	  give	  you	  some,”	  or	  the	  not-­‐so-­‐uncommon	  listing,	  “Yeah	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I’ve	  bought	  from	  ______,	  _______,	  _______,	  and	  _______.”	  	  The	  general	  impression	  one	  gets	  is	  that	  everyone	  with	  a	  prescription	  seems	  to	  be	  considered	  a	  potential	  amateur	  dealer,	  and	  the	  statistics	  suggest	  that	  such	  assumptions	  are	  correct	  more	  often	  than	  not.	  	  	   One	  of	  the	  aspects	  of	  stimulant	  medications	  that	  make	  them	  so	  attractive	  is	  that	  their	  action	  is	  very	  acute.	  	  Once	  you	  take	  a	  pill,	  there	  is	  an	  onset	  period	  (usually	  30	  minutes)	  followed	  by	  a	  clear	  period	  of	  drug	  action	  (generally	  4-­‐5	  hours)	  marked	  by	  increased	  attention	  and	  focus.	  	  Once	  that	  period	  of	  action	  ends,	  a	  brief	  “comedown”	  is	  experienced	  (generally	  30-­‐60	  minutes)	  characterized	  by	  sluggishness,	  dampened	  mood,	  and	  in	  some	  cases	  mild	  anhedonia.	  	  Once	  the	  comedown	  is	  over,	  there	  are	  no	  perceived	  effects	  of	  the	  drug.	  	  Because	  the	  effects	  of	  stimulant	  medications	  are	  so	  acute	  and	  consistent,	  users	  have	  a	  high	  level	  of	  control	  over	  their	  experience.	  	  The	  onset	  and	  offset	  of	  the	  drug	  is	  clearly	  defined,	  and	  the	  duration	  is	  relatively	  brief.	  	  Therefore,	  stimulant	  medications	  can	  easily	  be	  taken	  on	  an	  “as	  needed”	  basis,	  unlike	  other	  common	  psychoactive	  medicines	  such	  as	  antidepressants	  and	  antipsychotics,	  which	  have	  to	  be	  taken	  daily	  on	  regular	  schedules	  to	  achieve	  their	  desired	  effects.	  	  	  	   Research	  shows	  that,	  in	  general,	  people	  do	  not	  view	  stimulant	  medications	  as	  particularly	  harmful.	  	  This	  is	  likely	  due	  in	  part	  to	  the	  fact	  that	  they	  are	  prescription	  medicines.	  	  They	  are	  formulated	  and	  administered	  by	  virtue	  of	  their	  positive	  effects,	  and	  their	  responsible	  use	  is	  supported	  by	  an	  overwhelming	  majority	  of	  mental	  health	  professionals.	  	  Furthermore,	  these	  substances	  are	  relatively	  new,	  and	  there	  has	  not	  been	  enough	  time	  to	  observe	  any	  possible	  long-­‐term	  effects	  of	  their	  use.	  	  In	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one	  study,	  70%	  of	  students	  who	  had	  illicitly	  used	  stimulant	  medications	  before	  perceived	  slight	  or	  no	  risk,	  physical	  or	  otherwise,	  associated	  with	  illicit	  stimulant	  use	  [Arria	  et	  al.,	  2008].	  	  Out	  of	  all	  the	  students	  surveyed	  about	  illicit	  stimulant	  use	  (including	  illicit	  users	  and	  non-­‐users),	  4%	  perceived	  no	  risk,	  22%	  perceived	  slight	  risk,	  42.2%	  perceived	  moderate	  risk,	  25.2%	  perceived	  great	  risk,	  and	  6.6%	  “couldn’t	  say”	  [Arria	  et	  al.,	  2008].	  	  Only	  one	  in	  four	  students	  perceived	  a	  great	  risk	  for	  illicit	  stimulant	  use.	  	  This	  demonstrates	  the	  general	  sentiment	  that	  college	  students	  have	  about	  illicit	  stimulant	  use,	  and	  the	  greater	  conversation	  doesn’t	  seem	  to	  indicate	  that	  anyone	  is	  really	  that	  worried	  about	  the	  growing	  illicit	  use	  of	  stimulants	  on	  college	  campuses.	  	  	   	  In	  a	  U.S.	  News	  health	  report,	  Dr.	  Brian	  Doyle,	  a	  clinical	  professor	  of	  psychiatry	  at	  Georgetown	  University	  Medical	  Center,	  responded	  this	  way	  when	  asked	  if	  there	  is	  a	  trend	  of	  stimulant	  abuse	  among	  college	  students:	  “It's	  like	  the	  psychological	  equivalent	  of	  using	  steroids	  to	  enhance	  physical	  performance.	  	  These	  students	  seem	  to	  be	  doing	  it	  with	  relative	  impunity,	  and	  it	  doesn't	  seem	  to	  be	  causing	  too	  much	  trouble	  since	  most	  use	  the	  drugs	  not	  to	  get	  high	  but	  to	  function	  better.	  	  So	  when	  exams	  are	  over,	  they	  go	  back	  to	  normal	  and	  stop	  abusing	  the	  drugs”	  
[Shulman,	  2008].	  	  This	  position	  seems	  to	  be	  the	  feeling	  of	  most	  people	  on	  this	  issue.	  	  It	  implies	  that	  there	  are	  no	  serious	  health	  risks	  associated	  with	  occasional	  use	  of	  stimulant	  medications	  for	  academic	  reasons	  during	  college,	  and	  there	  even	  seems	  to	  be	  a	  tacit	  acceptance	  of	  the	  practice	  as	  if	  it’s	  no	  big	  deal.	  	  	  	   When	  looking	  at	  the	  research	  as	  a	  whole,	  it	  seems	  clear	  that	  the	  majority	  of	  people	  aren’t	  too	  worried	  about	  the	  illicit	  use	  of	  stimulant	  medications,	  particularly	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for	  academic	  reasons.	  	  Students	  on	  average	  show	  only	  mild	  concern	  about	  potential	  health	  risks,	  and	  the	  data	  suggests	  that	  once	  you	  try	  stimulants,	  your	  concern	  about	  them	  decreases	  significantly.	  	  If	  the	  general	  sentiment	  continues	  to	  be	  one	  of	  nonchalance	  and	  tacit	  acceptance,	  then	  it	  is	  doubtless	  that,	  as	  more	  and	  more	  students	  give	  stimulants	  a	  try,	  their	  popularity	  on	  college	  campuses	  will	  continue	  to	  grow.	  	   These	  stimulant	  drugs	  have	  gained	  a	  widespread	  reputation	  as	  performance	  enhancers—“steroids	  for	  your	  brain”	  as	  one	  student	  put	  it—and	  the	  demand	  for	  them	  by	  the	  non-­‐prescribed	  continues	  to	  rise.	  	  The	  reality	  is	  that,	  in	  general,	  students	  are	  able	  to	  get	  more	  work	  done	  in	  a	  shorter	  amount	  of	  time	  with	  the	  aid	  of	  stimulant	  medication,	  regardless	  of	  whether	  they	  qualify	  for	  an	  ADHD	  diagnosis.	  	  This	  has	  two	  potentially	  attractive	  consequences:	  1)	  students	  are	  able	  to	  make	  better,	  more	  efficient	  use	  of	  their	  study	  time	  and	  ultimately	  perform	  better	  in	  their	  coursework,	  leading	  to	  better	  grades,	  and	  2)	  students	  can	  more	  easily	  maintain	  a	  reasonable	  level	  of	  academic	  performance	  while	  still	  regularly	  participating	  in	  popular	  extracurricular	  activities	  stereotypical	  of	  the	  college	  experience	  (e.g.	  partying,	  substance	  abuse).	  	  Whether	  they	  are	  used	  to	  get	  an	  academic	  leg	  up,	  to	  support	  other	  extracurricular	  habits,	  or	  some	  combination	  of	  the	  two	  can	  vary	  from	  person	  to	  person.	  	  This	  variety	  of	  enticements	  is	  a	  valuable	  explanation	  for	  the	  rapid	  rise	  in	  stimulant	  medication	  popularity.	  	  	  	   Some	  researchers	  have	  argued	  that	  these	  drugs	  really	  don’t	  work	  for	  most	  non-­‐ADHD	  students.	  	  They	  argue	  that	  the	  scientific	  data	  shows	  that	  non-­‐prescribed	  stimulant	  users	  “typically”	  have	  lower	  grade	  point	  averages	  than	  non-­‐users,	  and	  that	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therefore	  non-­‐prescribed	  use	  doesn't	  seem	  to	  be	  academically	  beneficial	  [Arria	  et	  
al.,	  2008;	  McCabe	  et	  al.,	  2005].	  	  However,	  does	  this	  statistic	  truly	  suggest	  this?	  	  Survey	  research	  has	  shown	  that	  academic	  stress	  is	  the	  most	  common	  reason	  for	  illicit	  stimulant	  use	  [Arria	  et	  al.,	  2008;	  DeSantis	  et	  al.,	  2008;	  Sharp	  &	  Rosén,	  
2007].	  	  Academic	  stress	  can	  comprise	  several	  factors,	  most	  commonly	  dissatisfaction	  with	  grades	  and	  heavy	  workload.	  	  Students	  at	  every	  performance	  level	  experience	  these	  academic	  stressors,	  but	  the	  intensity	  at	  which	  they	  are	  experienced	  almost	  surely	  increases	  as	  performance	  level	  decreases.	  	  If	  we	  control	  for	  academic	  motivation,	  then	  a	  student	  with	  a	  lower	  GPA	  will	  likely	  feel	  more	  pressured	  by	  his	  course	  load	  and	  unhappier	  with	  his	  grades.	  	  	  	   When	  this	  level	  of	  academic	  stress	  becomes	  debilitating,	  it	  might	  be	  more	  accurately	  described	  as	  “academic	  desperation”.	  	  Desperation	  is	  a	  powerful	  motivator,	  and	  it	  seems	  that	  those	  who	  feel	  academically	  desperate	  would	  be	  more	  likely	  to	  turn	  to	  stimulant	  medications	  for	  help.	  	  Using	  these	  medications	  can	  only	  ever	  lead	  to	  a	  fractional	  increase	  in	  performance	  (albeit	  that	  any	  increase	  is	  often	  considered	  significant),	  and	  if	  academically	  desperate	  students	  with	  poor	  GPAs	  use	  these	  stimulants,	  we	  should	  still	  expect	  them	  to	  yield	  relatively	  low	  GPAs.	  	  Remember	  that	  letter	  grades	  are	  not	  perceived	  the	  same	  way	  by	  all	  students.	  	  A	  student	  with	  a	  2.5	  GPA	  will	  be	  much	  happier	  with	  a	  B-­‐	  than	  a	  student	  with	  a	  3.8	  GPA.	  	  The	  only	  parameter	  of	  consequence	  is	  whether	  the	  illicit	  stimulant	  user	  is	  pleased	  with	  the	  effect	  these	  drugs	  have	  on	  his	  performance.	  	  If	  he	  is	  pleased	  with	  the	  improvements	  to	  his	  grades,	  then	  the	  drugs	  have	  worked	  for	  him.	  	  This	  is	  no	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different	  from	  the	  way	  clinicians	  infer	  stimulant	  efficacy	  in	  their	  ADHD	  patients	  (discussed	  in	  Chapter	  II).	  	   Students	  with	  higher	  GPAs	  to	  begin	  with	  are	  much	  less	  likely	  to	  experience	  academic	  desperation,	  and	  therefore	  are	  less	  likely	  to	  turn	  to	  stimulant	  medications	  for	  aid.	  	  This	  is	  not	  to	  say,	  however,	  that	  “smart”	  people	  never	  use	  these	  drugs.	  	  Many	  reports	  from	  the	  professional	  world	  suggest	  that	  overachievers	  are	  some	  of	  the	  most	  likely	  people	  to	  seek	  out	  stimulant	  medications.	  	  Dr.	  Gagy	  Cora,	  a	  psychiatrist	  from	  Florida,	  describes	  her	  stimulant	  prescribed	  patients:	  “They	  are	  extremely	  smart	  and	  very	  successful.	  	  We’re	  not	  talking	  about	  someone	  struggling	  to	  perform,”	  [Szalavitz,	  2009].	  	  The	  reality	  seems	  to	  be	  that	  baseline	  performance	  is	  irrelevant	  to	  the	  effectiveness	  of	  stimulants.	  	  In	  fact,	  several	  studies	  have	  shown	  that	  therapeutic	  doses	  of	  stimulant	  medications	  lead	  to	  noticeable	  improvements	  in	  attentiveness,	  working	  memory,	  and	  task	  saliency	  (motivation	  to	  perform	  a	  task)	  in	  normal	  adult	  volunteers	  [Devous	  et	  al.,	  2001;	  Ilieva	  et	  al.,	  2015].	  	  Why	  do	  students	  in	  distress	  seek	  out	  and	  use	  these	  drugs	  illicitly?	  	  Because	  they	  work!	  	  Simple	  reason	  would	  suggest	  as	  much.	  	  If	  they	  didn’t	  work,	  then	  it	  is	  unlikely	  that	  they	  would	  see	  such	  rapid	  and	  continuous	  growth	  in	  popularity.	  	   The	  theory	  that	  academic	  distress	  is	  a	  primary	  motivator	  for	  illicit	  stimulus	  use	  by	  college	  students	  seems	  intuitive,	  and	  it	  fits	  well	  with	  what	  the	  data	  show—that	  illicit	  stimulant	  users	  on	  average	  have	  lower	  GPAs	  that	  non-­‐users	  and	  that	  they	  report	  feeling	  stressed	  and	  overwhelmed	  by	  their	  academic	  workloads.	  	  This	  is	  probably	  the	  case	  with	  a	  large	  portion	  of	  illicit	  users,	  however	  there	  are	  many	  who	  do	  not	  fall	  in	  this	  category.	  	  The	  main	  issue	  that	  I	  think	  this	  explanation	  fails	  to	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address	  is	  the	  competitive	  nature	  of	  collegiate	  academia.	  	  For	  many	  students,	  college	  is	  essentially	  a	  four-­‐round	  qualifier	  for	  their	  professional	  careers.	  	  Those	  with	  a	  graduate	  education	  in	  their	  sights	  are	  competing	  against	  each	  other	  for	  higher	  grades,	  awards,	  and	  extracurricular	  opportunities	  to	  boost	  their	  résumés.	  	  In	  this	  very	  Darwinian	  environment,	  it’s	  “survival	  of	  the	  fittest”.	  	  Ideally,	  “the	  fittest”	  should	  be	  the	  more	  talented	  and	  disciplined	  students,	  and	  this	  is	  certainly	  true	  most	  of	  the	  time.	  	  But	  what	  happens	  when	  you	  throw	  a	  few	  bright	  students	  with	  ADHD	  diagnoses	  and	  stimulant	  prescriptions	  into	  the	  mix?	  	  	  	   Students	  with	  stimulant	  prescriptions	  take	  them	  to	  remain	  attentive	  during	  lectures	  and	  to	  focus	  when	  preparing	  for	  exams.	  	  They	  are	  able	  to	  focus	  so	  well	  when	  on	  stimulants	  that	  they	  can	  study	  for	  many	  hours	  at	  a	  time	  while	  still	  remaining	  efficient,	  allowing	  them	  to	  condense	  their	  studying	  into	  fewer,	  lengthier	  sessions	  (a.k.a.	  cramming).	  	  As	  a	  result	  they	  are	  able	  to	  outperform	  even	  some	  of	  their	  more	  diligent	  fellow	  students,	  while	  still	  having	  plenty	  of	  free	  time	  to	  waste.	  	  This	  really	  doesn’t	  seem	  just.	  	  How	  can	  it	  be?	  	  Only	  students	  diagnosed	  with	  ADHD	  are	  able	  to	  legally	  obtain	  these	  prescribed	  stimulant	  medications	  and	  use	  them	  to	  achieve	  what	  they	  individually	  deem	  to	  be	  a	  satisfactory	  level	  of	  performance,	  while	  the	  other	  “normal”	  students	  are	  all	  expected	  to	  achieve	  without.	  	  Simply	  put,	  one	  loosely	  defined	  group	  is	  given	  access	  to	  performance-­‐enhancing	  drugs,	  and	  those	  that	  fall	  outside	  that	  group	  are	  denied.	  	  What	  sort	  of	  response	  is	  this	  scenario	  likely	  to	  encourage?	  	  Under	  the	  current	  parameters,	  controversy	  is	  surely	  inevitable.	  	  Consider	  this	  simplified	  hypothetical:	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Student	  X	  is	  “normal”.	  	  	  	   Student	  Y	  is	  diagnosed	  with	  ADHD.	  	  	  	   On	  his	  own,	  X	  achieves	  a	  3.2	  GPA.	  	  	   On	  his	  own,	  Y	  is	  only	  capable	  of	  achieving	  a	  2.5	  GPA,	  clearly	  less	  than	  X.	  	  	  	   However,	  since	  he	  is	  prescribed	  to	  a	  stimulant,	  Y	  is	  able	  to	  achieve	  a	  3.5	  GPA.	  	  	   If	  X	  had	  access	  to	  a	  stimulant,	  he	  could	  have	  achieved	  a	  3.8	  GPA.	  	   It	  is	  clear	  that	  Y	  ultimately	  out-­‐performs	  X	  because	  of	  the	  stimulant	  boost.	  	  	  This	  example	  seems	  to	  strike	  everyone	  as	  just	  plain	  wrong,	  however	  it	  is	  a	  realistic	  scenario	  under	  the	  current	  convention.	  	  Though	  the	  intent	  of	  these	  stimulant	  prescriptions	  is	  to	  facilitate	  an	  adequate,	  satisfactory	  level	  of	  performance,	  this	  often	  means	  providing	  these	  students	  with	  a	  very	  real	  competitive	  edge.	  	  The	  not-­‐so-­‐surprising	  consequence	  is	  that	  undiagnosed,	  non-­‐prescribed	  students	  seek	  out	  and	  use	  these	  drugs	  illicitly	  to	  maintain	  their	  own	  competitiveness.	  	  And	  can	  we	  blame	  them?	  	  When	  others	  are	  given	  an	  unfair	  advantage,	  how	  else	  can	  we	  expect	  them	  to	  respond,	  given	  that	  the	  competitive	  consequences	  for	  them	  are	  so	  immediate?	  	  	  	   This	  is	  the	  “arms	  race”	  that	  we	  see	  all	  around	  us	  today.	  	  In	  the	  past	  decade,	  illicit	  abuse	  of	  these	  medications	  on	  college	  campuses	  has	  skyrocketed.	  	  Studies	  have	  shown	  that	  between	  15%	  and	  30%	  of	  college	  students	  use	  stimulant	  medications	  illicitly	  (without	  a	  prescription),	  and	  more	  than	  50%	  of	  college	  students	  with	  prescriptions	  divert	  at	  least	  part	  of	  their	  supply	  to	  non-­‐prescribed	  students	  
[Garnier	  et	  al.,	  2010].	  	  This	  fast-­‐growing	  “study-­‐drug”	  culture	  is	  eerily	  similar	  to	  the	  anabolic	  steroid	  controversy	  that	  plagued	  professional	  sports	  for	  decades,	  and	  it	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has	  done	  much	  to	  accelerate	  the	  negative	  shift	  in	  public	  sentiment	  toward	  stimulant	  medication.	  	  	   The	  problem	  is	  here,	  and	  it	  is	  real.	  	  Though	  it	  is	  hard	  to	  make	  many	  definitive	  statements	  about	  the	  illicit	  use	  of	  stimulant	  medications	  on	  college	  campuses	  with	  the	  research	  that	  has	  been	  done	  thus	  far,	  there	  are	  a	  few	  things	  that	  are	  very	  clear.	  	  Illicit	  stimulant	  use	  on	  college	  campuses	  is	  common,	  and	  it’s	  on	  the	  rise.	  	  It	  has	  become	  increasingly	  easy	  to	  acquire	  stimulant	  medications	  on	  college	  campuses,	  usually	  from	  peers	  with	  prescriptions.	  	  There	  is	  a	  wide	  impression	  among	  college	  students	  that	  stimulant	  medications	  are	  performance	  enhancers	  and	  that	  they	  are	  relatively	  safe.	  	  Students	  use	  them	  illicitly	  for	  a	  variety	  of	  reasons,	  but	  mostly	  for	  academic	  purposes—either	  to	  help	  themselves	  stay	  afloat	  or	  to	  remain	  competitive	  when	  others	  use	  them.	  	   	  This,	  however,	  is	  only	  the	  visible	  issue.	  	  Illicit	  use	  of	  stimulant	  medications	  on	  college	  campuses	  is	  becoming	  increasingly	  common,	  and	  this	  has	  prompted	  the	  obvious	  questions:	  Should	  we	  buckle	  down	  to	  prevent	  illicit	  stimulant	  use,	  and	  if	  so	  how?	  	  It	  seems	  as	  if	  there	  is	  no	  clear	  answer	  to	  this	  question.	  	  This	  dilemma,	  I	  believe,	  is	  what	  points	  us	  to	  the	  deeper	  issue.	  	  It	  is	  to	  this	  issue	  that	  I	  devote	  the	  next	  chapter.	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CHAPTER	  	  IV:	   THE	  DEEPER	  ISSUE	   	  	  	   In	  Chapter	  I,	  I	  explained	  the	  effects	  that	  prescription	  stimulants	  have	  on	  the	  brain.	  	  By	  increasing	  dopamine	  transmission	  in	  the	  brain	  centers	  responsible	  for	  reward	  processing,	  i.e.	  the	  mesocorticolimbic	  pathway,	  these	  drugs	  increase	  motivation	  for	  engaging	  in	  certain	  behaviors,	  which	  leads	  to	  increased	  attention	  and	  memory	  performance.	  	  I	  also	  explained	  the	  predominant	  theory	  that	  ADHD	  is	  an	  issue	  of	  chemical	  imbalance;	  specifically,	  people	  with	  ADHD	  suffer	  from	  consistently	  low	  dopamine	  activity	  in	  the	  brain’s	  reward/motivation	  centers,	  inhibiting	  their	  ability	  focus	  and	  retain	  information.	  	  This	  is	  the	  reason,	  according	  to	  the	  predominant	  theory,	  why	  stimulant	  medications	  are	  apt	  for	  treating	  ADHD.	  	  People	  with	  ADHD	  lack	  dopamine,	  and	  stimulant	  medications	  provide	  the	  dopamine.	  	   It	  should	  be	  noted,	  however,	  that	  this	  biochemical	  explanation	  for	  ADHD	  only	  exists	  because	  of	  the	  efficacy	  stimulants	  have	  demonstrated	  in	  relieving	  the	  relevant	  symptoms.	  	  Researchers	  did	  not	  discover	  that	  patients	  with	  ADHD	  had	  lower	  dopamine	  levels	  and	  then	  specifically	  design	  a	  drug	  to	  increase	  those	  dopamine	  levels	  (even	  with	  our	  current	  technology,	  such	  research	  would	  be	  intensive	  and	  difficult	  to	  conduct	  from	  an	  ethical	  perspective).	  	  In	  fact,	  the	  process	  was	  exactly	  the	  opposite.	  	  	  	   It	  was	  long	  observed	  that	  stimulants	  like	  amphetamine	  had	  noticeable	  physical	  and	  mental	  effects.	  	  While	  most	  researchers	  during	  the	  1940s	  were	  initially	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interested	  in	  their	  potential	  for	  physical	  performance-­‐enhancement	  (World	  War	  II	  was	  all	  that	  mattered	  at	  the	  time),	  it	  was	  quickly	  observed	  that	  people	  taking	  stimulants	  experienced	  increased	  focus	  and	  attentional	  motivation	  [Rasmussen,	  
2011].	  	  During	  the	  1950s	  and	  1960s,	  the	  golden	  age	  of	  psychiatry,	  clinical	  researchers	  began	  intuitively	  administering	  these	  drugs	  to	  patients	  who	  exhibited	  attention	  deficits,	  and	  the	  results	  were	  exactly	  what	  they	  expected.	  	  Decades	  later,	  animal	  researchers	  determined	  that	  these	  stimulants	  worked	  by	  increasing	  dopamine	  activity	  in	  the	  brain’s	  reward	  centers	  [Sulzer	  et	  al.,	  2005].	  	  Because	  they	  had	  such	  positive	  effects	  on	  people	  with	  ADHD,	  it	  was	  inferred	  that	  dopamine	  deficiency	  was	  the	  cause	  of	  ADHD.	  	   To	  be	  clear,	  we	  do	  not	  know	  for	  sure	  what	  the	  cause	  of	  ADHD	  is.	  	  We	  only	  know	  what	  we	  can	  infer	  from	  the	  responses	  of	  ADHD	  people	  to	  stimulant	  medications.	  	  This	  makes	  the	  biochemical	  model	  a	  soft	  one.	  	  According	  to	  this	  model,	  ADHD	  is	  a	  state	  of	  insufficient	  dopamine	  transmission	  in	  the	  mesocorticolimbic	  reward	  pathway.	  	  Of	  course	  there	  are	  those	  who	  have	  excessive	  dopamine	  transmission	  in	  these	  areas,	  which	  could	  manifest	  as	  psychotic	  symptoms.	  	  Then	  there	  are	  those	  in	  the	  “normal”	  range,	  i.e.	  those	  who	  have	  just	  enough	  dopamine	  transmission.	  	  And	  certainly	  there	  are	  those	  who	  exist	  closer	  to	  the	  fringes	  of	  this	  “normal”	  range,	  i.e.	  those	  who	  barely	  have	  enough	  and	  those	  who	  almost	  have	  too	  much.	  	  Indeed,	  we	  must	  assume,	  if	  the	  biochemical	  model	  for	  ADHD	  is	  correct,	  that	  there	  exists	  a	  complete	  spectrum	  of	  dopamine	  activity	  levels	  and	  that	  people	  exist	  at	  levels	  all	  along	  that	  spectrum.	  	  In	  light	  of	  this,	  there	  is	  one	  very	  obvious	  question:	  What	  is	  the	  threshold	  of	  dopamine	  activity	  that	  qualifies	  as	  ADHD?	  	  How	  can	  you	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differentiate	  someone	  that	  is	  just	  below	  this	  threshold	  from	  someone	  who	  is	  just	  above	  it?	  	  If	  ADHD	  is	  truly	  a	  specific,	  diagnosable	  disorder,	  then	  there	  should	  be	  a	  way	  to	  clearly	  differentiate	  between	  the	  just	  barely	  and	  almost	  ADHD	  people.	  	  Ideally,	  the	  medicine	  could	  be	  the	  test.	  	  	  	   Here	  is	  an	  experimental	  model	  we	  could	  use.	  	  We	  collect	  a	  group	  of	  participants	  that	  we,	  through	  psychological	  evaluation,	  have	  determined	  are	  fringe	  candidates	  for	  ADHD.	  	  We	  have	  each	  participant	  write	  a	  five-­‐page	  essay	  on	  a	  given	  topic,	  and	  we	  observe	  each	  of	  them	  as	  they	  write.	  	  We	  then	  ask	  them	  to	  report	  how	  they	  felt	  while	  completing	  the	  assignment.	  	  The	  next	  day	  we	  give	  each	  of	  the	  participants	  a	  standard	  dose	  of	  Adderall	  (approximately	  20mg)	  and	  have	  them	  write	  another	  five-­‐page	  essay	  on	  a	  comparable,	  but	  different,	  topic.	  	  We	  observe	  them	  as	  they	  write	  and	  ask	  them	  to	  report	  how	  they	  felt	  while	  completing	  the	  assignment	  while	  on	  Adderall.	  	  Our	  naïve	  hypothesis	  is	  that	  those	  who	  truly	  suffer	  from	  ADHD	  will	  perform	  better	  on	  Adderall	  and	  report	  feeling	  more	  attentive	  and	  motivated,	  and	  those	  who	  do	  not	  truly	  suffer	  from	  ADHD	  will	  not	  show	  or	  feel	  much	  improvement	  in	  their	  performance.	  	  If	  such	  a	  result	  were	  attainable,	  then	  it	  would	  validate	  ADHD	  as	  a	  disorder	  and	  Adderall	  as	  an	  effective	  medication.	  	   Of	  course,	  this	  is	  not	  what	  we	  would	  see.	  	  The	  results	  of	  this	  experiment	  would	  be	  completely	  null.	  	  All	  of	  the	  participants	  would	  show	  increased	  performance	  efficiency,	  and	  all	  would	  likely	  report	  feeling	  more	  attentive	  and	  motivated	  to	  complete	  the	  task.	  	  Indeed,	  it	  is	  impossible	  to	  confidently	  draw	  any	  line	  for	  ADHD	  qualification.	  	  Ultimately,	  we	  can’t	  ever	  really	  know	  who	  has	  it	  and	  who	  doesn't.	  	  If	  someone	  reports	  feeling	  as	  if	  they	  have	  ADHD	  and	  seems	  to	  fit	  within	  the	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broad	  personality	  grouping	  related	  to	  ADHD,	  then	  we	  can	  only	  assume	  that	  he	  has	  ADHD.	  	  That	  is,	  assuming	  that	  ADHD	  is	  a	  valid	  diagnosis.	  	  Many	  argue	  that	  it	  is	  not,	  and	  others	  even	  go	  so	  far	  as	  to	  call	  it	  fictitious	  [Schonwald	  &	  Lechner,	  2006].	  	  The	  kicker	  here	  is	  that	  these	  diagnosed	  people	  are	  given	  prescriptions	  for	  stimulant	  medications	  to	  alleviate	  their	  symptoms—medications	  that	  we	  can	  now	  clearly	  see	  provide	  the	  same	  effect	  to	  virtually	  everyone.	  	  With	  this	  level	  of	  uncertainty	  due	  to	  the	  subjective	  criteria	  for	  diagnosis,	  what	  is	  to	  stop	  people	  from	  faking	  the	  right	  symptoms	  in	  order	  to	  acquire	  a	  stimulant	  prescription?	  	  This,	  along	  with	  benevolent	  over-­‐prescription,	  could	  help	  account	  for	  the	  dramatic	  rise	  in	  the	  incidence	  of	  ADHD	  over	  the	  past	  few	  decades.	  	  	  	   This	  seems	  to	  have	  been	  the	  trend	  with	  Major	  League	  Baseball.	  	  In	  2009,	  the	  year	  that	  MLB	  officially	  banned	  stimulants	  due	  to	  their	  performance-­‐enhancing	  effects,	  28	  players	  had	  medically	  certified	  exemptions,	  meaning	  they	  were	  diagnosed	  with	  ADHD.	  	  One	  year	  later,	  in	  2010,	  the	  number	  of	  players	  with	  exemptions	  had	  climbed	  to	  103,	  about	  8%	  of	  all	  MLB	  players	  [Saletan,	  2009].	  	  In	  one	  year,	  the	  number	  of	  MLB	  players	  diagnosed	  as	  ADHD	  quadrupled.	  	  Why	  did	  this	  happen?	  	  Is	  it	  really	  believable	  that	  75	  players	  suddenly	  realized	  they	  had	  attention	  problems	  and	  were	  accurately	  diagnosed	  with	  ADHD,	  all	  in	  one	  year?	  	  Or	  is	  it	  more	  reasonable	  to	  assume	  that	  these	  players	  sought	  out	  diagnoses	  in	  order	  to	  get	  around	  the	  ban	  and	  use	  stimulants	  to	  boost	  their	  performance?	  	  I	  find	  the	  latter	  much	  more	  sensible.	  	  And	  if	  baseball	  players	  can	  seek	  out	  diagnoses	  to	  get	  prescribed	  stimulants,	  why	  not	  college	  students?	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   Given	  their	  history	  of	  widespread	  use	  in	  numerous	  settings	  (professional,	  academic,	  athletic,	  and	  military)	  and	  judging	  by	  the	  universality	  of	  their	  effects,	  it’s	  hard	  to	  see	  these	  drugs	  as	  anything	  other	  than	  enhancement	  therapy.	  	  And	  is	  a	  scantly	  supported	  diagnosis	  of	  ADHD	  really	  enough	  to	  warrant	  giving	  a	  person	  performance-­‐enhancing	  drugs	  that	  are	  denied	  to	  the	  rest	  of	  the	  non-­‐prescribed	  public?	  	  If	  we	  are	  going	  to	  buckle	  down	  on	  illicit	  stimulant	  use,	  it	  seems	  only	  fair	  that	  we	  buckle	  down	  equally	  on	  this	  deeper	  issue	  and	  openly	  address	  the	  question	  of	  ADHD	  legitimacy.	  	  	  	   Based	  on	  my	  analysis	  thus	  far,	  I	  find	  there	  to	  be	  little	  compelling	  evidence	  that	  ADHD	  is	  a	  clearly	  definable	  condition,	  and	  even	  less	  to	  support	  that	  ADHD	  warrants	  exclusive	  prescriptions	  to	  performance-­‐enhancing	  stimulants.	  	  That	  being	  said,	  I	  do	  not	  deny	  that	  there	  are	  surely	  people	  out	  there	  who	  suffer	  on	  the	  lower	  end	  of	  the	  dopamine	  activity	  spectrum.	  	  They	  probably	  do	  in	  fact	  qualify	  to	  be	  diagnosed	  with	  ADHD.	  	  But	  where	  does	  the	  line	  for	  qualification	  end?	  	  Who	  really	  knows?	  	  It	  is	  for	  these	  reasons	  that	  I	  believe	  ADHD,	  as	  currently	  defined	  and	  diagnosed	  by	  the	  DSM-­‐V,	  is	  an	  inherently	  flawed	  label,	  and	  that	  any	  disproportionate	  allotment	  of	  medical	  advantages	  tied	  to	  this	  label	  should	  be	  reevaluated.	  	  The	  question	  now	  becomes:	  What	  do	  we	  do	  about	  it?	  	  How	  should	  our	  understanding	  of	  ADHD	  and	  stimulant	  medications	  influence	  how	  we	  regulate	  these	  substances?	  	  In	  the	  next	  few	  chapters	  I	  will	  discuss	  potential	  solutions	  to	  this	  problem	  and	  project	  potential	  consequences	  for	  each	  method.	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CHAPTER	  	  V:	   THE	  CASE	  FOR	  PROHIBITION	  	  	   As	  I	  have	  shown,	  it	  is	  essentially	  impossible	  in	  the	  vast	  majority	  of	  cases	  to	  determine	  who,	  if	  anyone,	  truly	  qualifies	  as	  having	  ADHD.	  	  Those	  with	  ADHD	  are	  almost	  always	  treated	  using	  stimulant	  medications,	  and	  it	  is	  therefore	  unavoidable	  under	  the	  current	  paradigm	  that	  many	  people	  who	  do	  not	  truly	  need	  them	  are	  being	  granted	  access	  to	  them.	  	  Stimulants	  have	  an	  undeniable	  performance	  enhancing	  effect	  on	  virtually	  all	  who	  use	  them,	  so	  their	  disproportionate	  dissemination	  naturally	  creates	  an	  enhancement	  disparity.	  	  In	  a	  competitive	  arena	  such	  as	  collegiate	  academics	  where	  everyone	  is	  fighting	  to	  keep	  up,	  this	  leads	  to	  widespread	  illicit	  stimulant	  use.	  	  	  	   This	  alarming	  development	  has	  prompted	  new	  conversation	  about	  the	  issue	  of	  stimulant	  medications	  and	  ADHD	  in	  general.	  	  Many	  are	  calling	  ADHD	  a	  fictitious	  diagnosis	  and	  stimulant	  medications	  a	  threat	  to	  the	  integrity	  of	  education.	  	  From	  this	  platform,	  I	  will	  discuss	  the	  case	  for	  across-­‐the-­‐board	  restriction	  of	  stimulant	  medications.	  	   To	  address	  the	  issue	  of	  illicit	  stimulant	  use,	  we	  must	  first	  identify	  the	  root	  of	  the	  problem.	  	  This	  was	  the	  subject	  of	  the	  previous	  chapter,	  in	  which	  I	  revealed	  that	  the	  deeper	  issue	  is	  the	  widespread	  prescription	  of	  stimulant	  medications.	  	  This	  excessive	  prescribing,	  an	  unavoidable	  part	  of	  the	  current	  paradigm,	  created	  a	  door	  through	  which	  stimulants	  could	  enter	  the	  college	  world.	  	  Virtually	  all	  studies	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confirm	  that	  the	  most	  common	  sources	  of	  illicit	  stimulants	  are	  peers	  with	  prescriptions	  [Arria	  &	  DuPont,	  2010;	  DeSantis	  et	  al.,	  2013;	  McCabe	  et	  al.,	  2005].	  	  If	  the	  goal	  is	  to	  eliminate	  illicit	  stimulant	  use	  on	  college	  campuses,	  then	  the	  most	  efficient	  line	  of	  action	  would	  be	  to	  eliminate	  the	  source	  of	  these	  stimulants.	  	  By	  prohibiting	  the	  prescribing	  of	  stimulants	  to	  treat	  ADHD,	  the	  source	  of	  these	  drugs	  would	  be	  effectively	  cut	  off.	  	  With	  no	  prescribed	  peers	  from	  whom	  to	  acquire	  the	  drugs,	  illicit	  users	  would	  have	  nowhere	  to	  turn.	  	  	   Some	  may	  argue	  that,	  if	  prescriptions	  are	  cut	  off,	  the	  illicit	  users	  will	  simply	  turn	  to	  covert,	  non-­‐licensed	  stimulant	  manufacturers.	  	  This	  black	  market	  theory	  is	  plausible,	  but	  I	  find	  it	  unlikely.	  	  The	  sharp	  rise	  in	  illicit	  stimulant	  use	  on	  college	  campuses	  has	  closely	  accompanied	  the	  rise	  in	  the	  frequency	  of	  stimulant	  prescriptions	  for	  college	  students.	  	  As	  the	  supply	  has	  increased,	  so	  has	  the	  demand.	  	  Though	  it	  is	  doubtful	  that	  the	  elimination	  of	  prescription	  stimulants	  will	  immediately	  eradicate	  the	  illicit	  demand	  for	  them,	  it	  seems	  likely	  that	  such	  demand	  will	  progressively	  fall.	  	  The	  vast	  majority	  of	  students,	  over	  85%,	  report	  illicitly	  using	  these	  drugs	  for	  academic	  reasons,	  and	  they	  likely	  feel	  justified	  by	  the	  presence	  of	  the	  noticeable	  group	  of	  students	  who	  have	  legitimate	  access	  to	  them—an	  “if	  they	  can,	  why	  can’t	  I”	  mentality	  [Arria	  &	  DuPont,	  2010;	  DeSantis	  et	  al.,	  2013].	  	  With	  no	  one	  being	  granted	  access	  to	  these	  performance-­‐enhancers,	  students	  should	  no	  longer	  feel	  the	  need	  to	  use	  stimulants	  illicitly	  in	  order	  to	  keep	  up.	  	  	   There	  might	  also	  be	  additional	  benefits	  to	  this	  sort	  of	  prohibitory	  action.	  	  With	  prescription	  stimulants	  eliminated,	  mental	  health	  professionals	  would	  be	  forced	  to	  explore	  other	  treatment	  options	  for	  those	  who	  struggle	  with	  attention	  and	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motivation.	  	  Cognitive-­‐behavioral	  therapy	  (CBT)	  and	  meditation	  are	  two	  methods	  that	  have	  both	  been	  shown	  to	  attenuate	  the	  symptoms	  described	  by	  ADHD.	  	  In	  fact,	  in	  numerous	  studies,	  CBT	  has	  demonstrated	  symptom	  relief	  efficacy	  equal	  to	  stimulant	  medication	  [Lyons	  &	  Martin,	  2011].	  	  With	  such	  promising	  evidence	  already	  in	  publication,	  it	  is	  not	  unreasonable	  to	  hope	  that	  necessity	  will	  drive	  doctors	  and	  researchers	  to	  affirm	  and	  refine	  these	  alternative	  treatment	  techniques,	  filling	  the	  therapeutic	  gap	  left	  by	  prohibited	  stimulant	  medications.	  	   However,	  when	  discussing	  potential	  decisions	  one	  must	  also	  consider	  any	  potentially	  negative	  consequences.	  	  Because	  this	  prohibitory	  approach	  is	  designed	  to	  lean	  on	  the	  “safer”	  side,	  the	  negative	  consequences	  are	  not	  readily	  apparent.	  	  However,	  there	  is	  one	  issue	  that	  could	  be	  of	  serious	  concern.	  	  What	  if,	  for	  a	  select	  group	  of	  students,	  stimulant	  medication	  is	  the	  only	  treatment	  method	  that	  effectively	  relieves	  their	  ADHD	  symptoms?	  	  It	  could	  be	  possible	  that,	  even	  though	  other	  non-­‐pharmaceutical	  methods	  have	  proven	  equally	  effective	  for	  most	  patients,	  there	  are	  still	  a	  select	  few	  who	  only	  respond	  meaningfully	  to	  stimulant	  medication.	  	  If	  this	  were	  the	  case,	  it	  would	  not	  be	  justifiable	  to	  deny	  these	  individuals	  the	  treatment	  they	  need.	  	  	  	   This	  could	  be	  a	  slippery	  slope	  for	  this	  policy,	  however.	  	  If	  you	  must	  allow	  prescriptions	  for	  those	  who	  truly	  need	  them,	  then	  you	  once	  again	  have	  to	  establish	  the	  line	  that	  defines	  legitimate	  need.	  	  Though	  this	  might	  be	  theoretically	  possible	  if	  patients	  are	  forced	  to	  undergo	  extensive	  trials	  for	  every	  other	  treatment	  option	  with	  no	  signs	  of	  improvement	  before	  being	  referred	  to	  stimulant	  medication,	  such	  testing	  would	  be	  expensive,	  time-­‐consuming,	  and	  ultimately	  unrealistic.	  	  More	  likely,	  the	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line	  would	  slowly	  begin	  the	  regress	  again	  toward	  the	  mean,	  allowing	  for	  more	  and	  more	  students	  to	  acquire	  stimulant	  prescriptions,	  and	  we	  might	  end	  up	  no	  better	  off	  than	  when	  we	  started.	  	   But	  what	  else	  could	  we	  do?	  	  We	  have	  examined	  the	  possibility	  of	  allowing	  no	  one	  access	  to	  prescription	  stimulants,	  and	  it	  seems	  like	  this	  might	  lead	  to	  even	  more	  controversy	  down	  the	  line.	  	  This	  being	  the	  case,	  perhaps	  we	  should	  consider	  a	  more	  liberal	  option.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  




CHAPTER	  	  VI:	   THE	  CASE	  FOR	  ENHANCEMENT	  	  	   Stimulant	  medications	  create	  a	  very	  tricky	  situation.	  	  Given	  the	  failure	  of	  the	  current	  regulatory	  policies,	  it	  seems	  that	  this	  sort	  of	  issue	  lends	  itself	  to	  an	  “all-­‐or-­‐none”	  type	  of	  thinking.	  	  That	  is,	  either	  no	  one	  should	  have	  access	  to	  stimulants	  or	  everyone	  should.	  	  In	  the	  last	  chapter	  I	  discussed	  the	  pros	  and	  cons	  of	  a	  prohibitory,	  or	  “none”,	  approach.	  	  Though	  this	  method	  does	  address	  certain	  issues,	  it	  seemed	  to	  create	  others.	  	  When	  all	  things	  are	  considered,	  the	  two	  key	  problems	  appear	  to	  be:	  1)	  some	  people	  truly	  require	  stimulant	  medications	  to	  function	  properly	  and	  many	  others	  find	  them	  therapeutic	  and	  beneficial,	  and	  2)	  prescription	  stimulants,	  in	  many	  cases,	  can	  provide	  an	  unfair	  competitive	  academic	  edge	  for	  the	  user	  over	  other	  non-­‐prescribed	  people.	  	  The	  prohibitory	  approach	  directly	  addresses	  the	  second	  problem,	  but	  ultimately	  it	  seems	  to	  exacerbate	  the	  first	  one.	  	  So	  what	  if	  we	  approach	  this	  from	  the	  opposite	  angle?	  	  If	  “none”	  doesn’t	  do	  the	  trick,	  maybe	  “all”	  will.	  	   Back	  pain	  is	  a	  sort	  of	  general	  ailment,	  meaning	  that	  there	  is	  a	  grouping	  of	  symptoms	  that,	  when	  experienced	  by	  a	  patient,	  are	  labeled	  as	  “back	  pain”.	  	  In	  most	  cases,	  there	  is	  no	  standard	  cure	  for	  back	  pain.	  	  Rather,	  patients	  are	  generally	  prescribed	  to	  a	  type	  of	  opiate	  therapy	  to	  treat	  their	  symptoms.	  	  Virtually	  anyone	  experiencing	  the	  appropriate	  symptoms	  for	  “back	  pain”	  is	  eligible	  for	  opiate	  therapy,	  barring	  some	  ulterior	  health	  concerns.	  	  The	  important	  thing	  to	  notice	  here	  is	  that	  in	  many,	  if	  not	  most,	  cases,	  people	  are	  not	  diagnosed	  with	  a	  specific,	  curable	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disorder	  as	  the	  source	  of	  their	  back	  pain.	  	  Rather,	  most	  people	  are	  simply	  diagnosed	  as	  suffering	  from	  symptomatic	  “back	  pain”	  and	  are	  given	  the	  drugs	  necessary	  to	  curb	  their	  symptoms.	  	  Opiate	  therapy	  is	  viewed	  as	  a	  method	  of	  symptom	  relief,	  not	  a	  cure	  for	  a	  specific	  disorder,	  and	  therefore	  it	  is	  much	  easier	  for	  the	  average	  person	  to	  acquire.	  	  Are	  opiates	  addictive?	  	  Absolutely.	  	  Are	  they	  commonly	  abused?	  	  Of	  course.	  	  Are	  they	  potentially	  harmful?	  	  If	  abused,	  certainly.	  	  However,	  there	  are	  many	  people	  out	  there	  who	  can	  only	  find	  relief	  from	  their	  symptomatic	  pain	  by	  taking	  prescription	  opiates,	  and	  this	  has	  been	  reason	  enough	  to	  keep	  these	  potentially	  dangerous	  drugs	  readily	  available	  to	  the	  public.	  	   Now	  imagine	  a	  world	  where	  stimulant	  medications	  are	  regarded	  in	  the	  same	  manner	  as	  opiate	  medications.	  	  In	  this	  world,	  the	  clinical	  label	  “ADHD”	  has	  been	  abandoned	  by	  the	  psychiatric	  community,	  and	  the	  group	  of	  symptoms	  that	  once	  added	  up	  to	  ADHD	  are	  now	  viewed	  as	  a	  general	  ailment	  rather	  than	  a	  specific	  diagnosable	  disorder.	  	  In	  this	  world,	  almost	  anyone	  who	  experiences	  distress	  by	  “attention	  deficit”	  is	  eligible	  for	  stimulant	  therapy,	  the	  same	  way	  that	  almost	  anyone	  distressed	  by	  “back	  pain”	  is	  eligible	  for	  opiate	  therapy.	  	  People	  who	  feel	  that	  they	  struggle	  to	  focus	  and	  experience	  distress	  as	  a	  result	  of	  this	  struggle	  need	  only	  visit	  a	  doctor.	  	  If	  the	  doctor	  is	  convinced	  that	  a	  patient’s	  symptoms	  and	  distress	  are	  genuine,	  then	  that	  patient	  is	  immediately	  eligible	  for	  stimulant	  therapy.	  	  	  	   This	  scenario	  may	  seem	  radical	  and	  farfetched	  at	  first,	  but	  in	  reality	  it	  is	  little	  more	  than	  a	  stretch	  from	  our	  current	  way	  of	  thinking	  about	  stimulant	  medications.	  	  Under	  the	  present	  paradigm,	  patients	  must	  meet	  the	  criteria	  necessary	  for	  an	  ADHD	  diagnosis	  is	  order	  to	  be	  granted	  access	  to	  prescription	  stimulants.	  	  This	  has	  led	  to	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controversy	  because	  ADHD,	  though	  inherently	  ambiguous,	  is	  regarded	  as	  a	  specific	  disorder,	  and	  stimulant	  medications,	  though	  ubiquitous	  in	  their	  effects,	  are	  seen	  as	  a	  “cure”	  for	  ADHD.	  	  But	  what	  if	  the	  paradigm	  changed?	  	  If	  we	  view	  “attention	  deficit”	  as	  a	  general	  sort	  of	  ailment	  whose	  symptoms	  come	  and	  go	  with	  different	  settings	  and	  external	  pressures,	  it	  instantly	  becomes	  a	  more	  acceptable	  and	  relatable	  condition.	  	  Surely	  most	  of	  us	  have	  experienced	  times	  when	  we	  struggled	  to	  focus	  on	  certain	  tasks.	  	  What	  if	  even	  occasional	  attentional	  struggles	  warranted	  access	  to	  stimulant	  therapy?	  	  One	  doesn’t	  need	  to	  suffer	  from	  constant,	  uninterrupted	  “back	  pain”	  in	  order	  to	  receive	  opiate	  medication.	  	  Occasional	  pain	  flare-­‐ups	  are	  enough	  to	  warrant	  a	  prescription	  to	  be	  taken	  “as	  needed”.	  	  Similarly,	  perhaps	  one	  shouldn’t	  need	  to	  suffer	  from	  constant,	  uninterrupted	  “attention	  deficit”	  in	  order	  to	  receive	  stimulant	  medication.	  	  Perhaps	  intermittent	  struggles	  with	  focus	  should	  be	  enough	  to	  warrant	  an	  “as	  needed”	  prescription.	  	   At	  the	  root	  of	  all	  this,	  there	  is	  a	  case	  to	  be	  made	  for	  individual	  autonomy	  when	  it	  comes	  to	  therapeutic	  substance	  use.	  	  Ronald	  Bailey	  makes	  this	  case	  in	  his	  article,	  “The	  Battle	  for	  Your	  Brain”	  [Bailey,	  2003].	  	  Pointing	  to	  the	  examples	  of	  Prozac	  (an	  antidepressant)	  and	  Ritalin	  (a	  stimulant),	  he	  asserts	  that	  drugs	  like	  these	  provide	  real	  therapeutic	  benefits	  to	  many	  people,	  and	  that	  those	  people	  should	  be	  entitled	  to	  access	  to	  these	  drugs	  if	  they	  choose	  to	  use	  them	  [Bailey,	  2003].	  	  In	  his	  view,	  broad	  concerns	  about	  the	  societal	  impact	  of	  increased	  neuro-­‐pharmaceutical	  therapy	  are	  not	  grounds	  enough	  to	  deprive	  individual	  people	  of	  treatments	  that	  they	  perceive	  as	  beneficial	  [Bailey,	  2003].	  	  This	  is	  a	  very	  liberal	  perspective	  concerned	  with	  the	  individual’s	  right	  to	  self-­‐determination.	  	  Within	  the	  scope	  of	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medicine,	  the	  principle	  of	  Autonomy	  maintains	  that	  every	  individual	  is	  entitled	  to	  accept	  or	  reject	  whatever	  treatment	  is	  offered	  them,	  and	  the	  principle	  of	  Beneficence	  maintains	  that	  doctors	  are	  obligated	  to	  reduce	  suffering	  and	  promote	  wellbeing	  by	  whatever	  means	  necessary	  [Beauchamp	  &	  Childress,	  2009].	  	  	  	   This	  means	  that	  if	  a	  patient	  suffers	  from	  “back	  pain”,	  the	  doctor	  is	  responsible	  for	  providing	  the	  possible	  treatment	  options	  and	  helping	  the	  patient	  make	  an	  informed	  decision.	  	  If	  the	  doctor	  believes	  that	  surgery	  might	  provide	  a	  more	  permanent	  solution,	  but	  the	  patient	  refuses	  the	  operation,	  the	  doctor	  must	  respect	  the	  patient’s	  autonomous	  decision	  and	  is	  benevolently	  obligated	  to	  provide	  the	  medication	  necessary	  to	  relieve	  the	  patient’s	  painful	  symptoms.	  	  Conversely,	  if	  the	  doctor	  believes	  that	  opiate	  medication	  is	  the	  most	  effective	  way	  to	  control	  the	  pain,	  but	  the	  patient	  is	  unwilling	  to	  take	  the	  drugs,	  the	  doctor	  must	  respect	  the	  patient’s	  choice	  and	  must	  offer	  other	  treatment	  options	  if	  they	  are	  available.	  	  Similarly,	  if	  a	  patient	  suffers	  from	  “attention	  deficit”,	  the	  doctor	  is	  obligated	  to	  relieve	  these	  symptoms.	  	  If	  the	  doctor	  believes	  that	  CBT	  is	  the	  ideal	  treatment	  method,	  but	  the	  patient	  refuses	  and	  opts	  for	  stimulant	  medication,	  the	  doctor	  should	  be	  obligated	  to	  respect	  the	  patient’s	  autonomous	  decision.	  	  If	  an	  individual	  experiences	  a	  therapeutic	  benefit	  (i.e.	  increased	  attention/focus	  and	  decreased	  subjective	  distress)	  by	  taking	  stimulant	  medications,	  who	  are	  we	  to	  refuse	  this	  individual’s	  right	  to	  autonomy	  and	  beneficence?	  	   Bailey	  advocates	  for	  the	  individual’s	  right	  to	  enhancement.	  	  That	  is,	  he	  believes	  that	  everyone	  should	  have	  the	  right	  to	  take	  performance-­‐enhancing	  drugs	  if	  they	  believe	  it	  is	  in	  their	  best	  interests	  [Bailey,	  2003].	  	  The	  system	  under	  which	  this	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sort	  of	  prescription	  distribution	  might	  occur	  is	  simple.	  	  If	  you	  are	  dissatisfied	  with	  your	  current	  attentional	  performance	  and	  want	  to	  experience	  the	  benefits	  of	  stimulant	  medications,	  you	  simply	  visit	  your	  local	  doctor.	  	  You	  explain	  to	  the	  doctor	  that	  you	  are	  dissatisfied	  with	  your	  current	  attentional	  performance	  and	  want	  to	  try	  stimulant	  therapy.	  	  The	  doctor	  explains	  the	  potential	  risks	  that	  accompany	  stimulant	  use	  and	  screens	  you	  for	  any	  conditions	  that	  might	  put	  you	  at	  increased	  risk	  with	  stimulant	  use.	  	  After	  discussing	  the	  appropriate	  information	  with	  your	  doctor,	  if	  you	  still	  think	  you	  could	  benefit	  from	  stimulant	  use	  then	  you	  should	  be	  eligible	  for	  a	  prescription.	  	  Under	  this	  paradigm,	  anyone	  who	  derives	  therapeutic	  benefit	  from	  stimulants	  without	  significant	  risk	  of	  harmful	  side	  effects	  is	  granted	  access	  to	  them.	  	  	  	   Of	  course	  there	  should	  be	  measures	  taken	  to	  discourage	  and	  hopefully	  prevent	  stimulant	  drug	  abuse,	  however	  the	  potential	  for	  such	  abuse	  is	  not	  sufficient	  to	  justify	  excessive	  restriction	  of	  these	  substances.	  	  Our	  society	  is	  riddled	  with	  examples	  of	  autonomy	  prioritized.	  	  Tobacco	  use	  commonly	  leads	  to	  emphysema,	  lung	  cancer,	  and	  heart	  disease	  and	  is	  highly	  addictive,	  yet	  we	  allow	  anyone	  age	  eighteen	  or	  older	  to	  buy	  it	  from	  the	  nearest	  gas	  station.	  	  Alcohol	  is	  destructive	  to	  the	  heart,	  kidneys,	  and	  pancreas	  and	  has	  a	  high	  potential	  for	  abuse,	  yet	  it	  is	  readily	  and	  legally	  available	  to	  anyone	  age	  twenty-­‐one	  or	  older.	  	  When	  it	  comes	  to	  these	  clearly	  dangerous	  substances,	  we	  defer	  to	  the	  individual’s	  personal	  judgment;	  ergo,	  you	  can	  consume	  as	  much	  of	  these	  drugs	  as	  you	  want	  as	  often	  as	  you	  want	  as	  long	  as	  you	  don't	  interfere	  negatively	  with	  the	  lives	  of	  others.	  	  If	  we	  respect	  autonomous	  choice	  when	  it	  comes	  to	  these	  crude,	  destructive	  substances,	  why	  should	  our	  approach	  to	  refined,	  effective	  substances	  be	  any	  different?	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   When	  it	  comes	  to	  neurological	  enhancement	  technologies	  like	  stimulant	  medications,	  there	  are	  several	  complaints	  that	  are	  commonly	  submitted.	  	  Bailey	  identifies	  many	  of	  these,	  and	  I	  will	  comment	  in	  order	  on	  the	  three	  that	  I	  find	  most	  relevant	  and	  important;	  namely	  that	  neurological	  enhancements	  1)	  undermine	  good	  character	  and	  personal	  responsibility,	  2)	  erode	  authenticity	  and	  promote	  “dubious	  norms”,	  and	  3)	  are	  either	  anti-­‐egalitarian	  of	  self-­‐defeating.	  	  	  	   The	  claim	  that	  it	  is	  immoral	  and	  irresponsible	  to	  use	  stimulant	  medications	  for	  their	  enhancing	  effects	  seems	  unfounded	  to	  me.	  	  There	  seems	  to	  be	  an	  underlying	  stoicism	  in	  the	  way	  we	  approach	  academic	  and	  professional	  life.	  	  Society	  tells	  us	  that	  the	  acceptable	  way	  to	  overcome	  challenges	  in	  life	  is	  to	  struggle	  hard	  with	  oneself,	  to	  work	  with	  others,	  and	  to	  endure	  necessary	  pain	  and	  sacrifice.	  	  This	  tough	  love	  mentality	  implies	  that	  there	  is	  some	  ideal	  virtue	  to	  “succeeding	  on	  your	  own	  steam”,	  and	  that	  using	  any	  artificial	  or	  external	  agents	  to	  increase	  one’s	  own	  performance	  is	  somehow	  dishonorable.	  	  I	  find	  this	  sort	  of	  thinking	  to	  be	  shortsighted	  and,	  in	  a	  sense,	  hypocritical.	  	  	  	   We	  humans	  are	  constantly	  striving	  for	  new	  ways	  to	  enhance	  performance	  and	  increase	  efficiency—from	  the	  wheel	  to	  the	  microwave—and	  we	  make	  no	  exception	  for	  our	  bodies.	  	  Coffee	  is	  an	  excellent	  example	  of	  a	  ubiquitous	  performance	  enhancer.	  	  Caffeine	  is	  the	  most	  widely	  used	  stimulant	  substance	  on	  the	  planet,	  and,	  like	  other	  more	  potent	  stimulants,	  it	  promotes	  alertness	  and	  focus	  by	  increasing	  dopamine	  activity	  in	  the	  mesolimbic	  reward	  pathway	  [Nehlig	  et	  al.,	  
1992].	  	  While	  most	  of	  us	  simply	  use	  caffeine	  via	  coffee	  to	  enhance	  our	  general	  alertness	  throughout	  the	  day,	  many	  use	  it	  in	  higher	  quantity	  to	  boost	  cognitive	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performance.	  	  However,	  I	  don’t	  hear	  anyone	  decrying	  the	  use	  of	  caffeine	  via	  coffee	  as	  a	  study	  aid	  (except	  for	  the	  Mormons	  of	  course,	  who,	  to	  avoid	  the	  evils	  of	  coffee,	  adopted	  a	  Native	  American	  tea	  containing	  ephedrine,	  a	  naturally	  occurring	  stimulant	  structurally	  analogous	  to	  methamphetamine).	  	  We	  have	  unquestioningly	  accepted	  this	  practice,	  even	  though	  it	  is	  clearly	  a	  form	  of	  performance	  enhancement,	  albeit	  mild.	  	  It	  seems	  that	  it	  is	  the	  strength	  and	  efficiency	  of	  stimulant	  medications	  that	  set	  them	  apart	  from	  other	  stimulants	  like	  caffeine;	  but	  can	  we	  really	  draw	  a	  moral	  distinction	  here	  based	  solely	  on	  the	  strength	  of	  the	  shared	  effects?	  	  It	  just	  doesn’t	  seem	  logical.	  	  	  	   I	  also	  believe	  that	  characterizing	  prescription	  stimulant	  use	  as	  irresponsible	  is	  shortsighted.	  	  Certainly	  we	  would	  all	  agree	  that	  the	  reckless	  use	  of	  stimulants	  for	  recreational	  purposes	  is	  irresponsible,	  however	  this	  is	  not	  the	  sort	  of	  stimulant-­‐related	  behavior	  that	  we	  are	  discussing.	  	  For	  people	  seeking	  to	  maximize	  cognitive	  performance,	  especially	  those	  who	  struggle	  with	  attention	  and	  focus,	  it	  seems	  that	  using	  stimulants	  in	  controlled	  doses	  is	  in	  fact	  the	  responsible	  thing	  to	  do.	  	  Struggles	  demand	  solutions,	  and	  if	  an	  individual	  struggles	  with	  attention,	  the	  responsible	  think	  to	  do	  is	  to	  resolve	  that	  struggle,	  even	  if	  the	  solution	  comes	  in	  the	  form	  of	  stimulant	  medications.	  	  	  	   There	  are	  those	  who	  suggest	  that	  stimulant	  use	  degrades	  authenticity	  and	  promotes	  normative	  behavior	  [Arria	  &	  DuPont,	  2010].	  	  This	  argument	  seems	  to	  imply	  that	  allowing	  external	  forces	  to	  influence	  your	  mind	  makes	  one’s	  behavior	  inauthentic.	  	  Is	  it	  possible,	  then,	  for	  anyone	  to	  be	  truly	  authentic?	  	  Stimulant	  medications	  can	  augment	  one’s	  capacity	  for	  attention	  and	  focus,	  however	  they	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cannot	  implant	  ideas.	  	  They	  can	  impact	  one’s	  personality	  and	  patterns	  of	  behavior,	  but	  so	  can	  just	  about	  anything.	  	  Enhancing	  performance	  and/or	  altering	  behavior	  have	  no	  bearing	  on	  authenticity.	  	  As	  Bailey	  proposes,	  consider	  a	  religious	  convert.	  	  If	  a	  man	  undergoes	  a	  dramatic	  religious	  conversion	  such	  that	  his	  personality	  and	  behavioral	  patterns	  are	  changed,	  does	  this	  make	  him	  inauthentic?	  	  Surely	  not.	  	  	  	   Perhaps	  the	  loudest	  argument	  against	  neurological	  enhancement	  technologies	  is	  that	  they	  are	  anti-­‐egalitarian	  or	  self-­‐defeating.	  	  The	  idea	  here	  is	  that	  certain	  people	  will	  have	  greater	  access	  to	  stimulant	  medications	  than	  others,	  and	  that	  it	  is	  therefore	  unfair	  to	  allow	  those	  with	  access	  to	  benefit	  while	  those	  without	  access	  cannot	  benefit.	  	  This	  argument	  is	  weak	  at	  best.	  	  Should	  we	  also	  bar	  parents	  with	  substantial	  means	  from	  sending	  their	  children	  to	  exclusive	  universities	  because	  many	  others	  cannot	  afford	  to?	  	  Of	  course	  not.	  	  Besides,	  the	  monetary	  costs	  for	  stimulant	  medications	  are	  unlikely	  to	  result	  in	  such	  drastic	  disparities.	  	  If	  anything,	  widespread	  access	  to	  stimulants	  could	  result	  in	  increased	  social	  equality.	  	  	  	   Then	  there	  are	  those	  who	  suggest	  that	  egalitarian	  distribution	  of	  stimulant	  medications,	  once	  achieved,	  would	  defeat	  the	  purpose	  of	  having	  them	  in	  the	  first	  place.	  	  The	  argument	  is	  that	  since	  certain	  people	  use	  these	  drugs	  to	  level	  the	  functional	  playing	  fields,	  granting	  everyone	  access	  to	  these	  substances	  would	  negate	  that	  leveling	  effect.	  	  However,	  there	  is	  no	  real	  reason	  to	  think	  that	  this	  would	  happen.	  	  The	  vast	  majority	  of	  people	  who	  use	  stimulants	  now	  do	  so	  because	  they	  experience	  some	  personal	  benefit.	  	  They	  are	  better	  able	  to	  meet	  their	  own	  performance	  expectations.	  	  They	  are	  better	  able	  to	  focus	  their	  minds	  and	  block	  out	  the	  constant	  barrage	  of	  cognitive	  distractions.	  	  If	  the	  restrictive	  controls	  on	  these	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CHAPTER	  	  VII:	   THE	  PRINCIPLED	  APPROACH	  	  	   As	  evidenced	  by	  the	  persistent	  and	  growing	  debate	  surrounding	  the	  legitimacy	  of	  stimulant	  medications	  and	  their	  distribution,	  making	  definitive	  ethical	  decisions	  about	  these	  issues	  is	  not	  easy.	  	  Thus	  far	  we	  have	  described	  the	  current	  state	  of	  affairs	  and	  discussed	  two	  different	  approaches	  to	  improving	  the	  situation.	  	  The	  two	  alternative	  solutions	  are	  inherently	  polarized,	  and	  this	  seems	  to	  appeal	  to	  the	  polarized	  nature	  of	  our	  political	  system.	  	  Look	  for	  people	  supporting	  increased	  regulation	  and	  prohibition	  of	  mind-­‐altering	  drugs,	  and	  you	  will	  likely	  find	  them	  in	  the	  conservative	  political	  camp.	  	  Look	  for	  people	  supporting	  decreased	  regulation	  and	  increased	  availability	  of	  mind-­‐altering	  drugs,	  and	  you	  will	  likely	  find	  them	  in	  the	  progressive	  political	  camp.	  	  However,	  this	  discussion	  is	  more	  than	  a	  political	  issue—it’s	  a	  personal	  health	  issue.	  	  This	  being	  the	  case,	  it	  seems	  silly	  to	  allow	  political	  affiliations	  to	  dictate	  how	  we	  reach	  our	  conclusions.	  	  When	  the	  well-­‐being	  of	  others	  is	  at	  issue,	  the	  only	  acceptable	  way	  to	  make	  decisions	  is	  a	  systematic	  ethical	  approach.	  	  	   The	  method	  that	  I	  find	  most	  apt	  for	  addressing	  these	  sorts	  of	  bioethical	  issues	  is	  Principlism.	  	  This	  ethical	  system	  is	  concerned	  with	  four	  key,	  distinct	  principles:	  1)	  Autonomy,	  the	  obligation	  to	  respect	  the	  individual’s	  right	  to	  self-­‐determination,	  2)	  Beneficence,	  the	  obligation	  to	  relieve	  suffering	  and	  improve	  the	  peoples	  lives,	  3)	  Nonmaleficence,	  the	  obligation	  to	  do	  no	  harm,	  and	  4)	  Justice,	  the	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obligation	  to	  promote	  fairness	  and	  equality,	  especially	  regarding	  the	  distribution	  of	  benefits	  and	  burdens	  [Beauchamp	  &	  Childress,	  2009].	  	  Each	  of	  these	  principles	  carries	  inherent	  moral	  weight,	  and	  the	  goal	  of	  any	  decision-­‐making	  process	  should	  be	  to	  weigh	  and	  balance	  these	  principles	  in	  the	  most	  equitable	  way	  possible.	  	  This	  means	  assessing	  the	  situation	  according	  to	  each	  principle	  and	  identifying	  the	  best	  way	  to	  reconcile	  each	  principled	  position	  with	  the	  others	  [Beauchamp	  &	  Childress,	  
2009].	  	  Ultimately,	  a	  moral	  harmony	  is	  struck	  whereby	  all	  four	  principles	  are	  respected	  and	  reconciled	  appropriately.	  	   Autonomy	  is	  perhaps	  the	  most	  prioritized	  factor	  in	  Principlist	  ethics,	  and	  for	  this	  reason	  we	  will	  discuss	  it	  first.	  	  When	  an	  individual’s	  personal	  health	  is	  at	  stake,	  the	  need	  for	  self-­‐determination	  is	  paramount.	  	  In	  every	  scenario,	  it	  is	  the	  patient’s	  body	  and	  life	  on	  the	  line.	  	  Each	  individual	  experiences	  life	  uniquely,	  and	  only	  the	  patient	  is	  subjectively	  aware	  of	  his	  pain	  and	  distress	  and	  the	  extent	  to	  which	  it	  is	  relieved.	  	  Additionally,	  the	  patient	  is	  the	  one	  who	  is	  treated,	  and	  it	  is	  he	  who	  must	  endure	  the	  consequences	  of	  said	  treatment.	  	  What	  this	  means,	  first	  and	  foremost,	  is	  that	  no	  patient	  should	  be	  treated	  against	  his	  will.	  	  This	  is	  the	  one	  standard	  that	  is	  completely	  non-­‐negotiable.	  	  Secondarily,	  this	  means	  that	  the	  patient	  should	  be,	  within	  reason,	  allowed	  to	  select	  the	  form	  of	  treatment	  he	  receives.	  	  After	  all,	  it	  is	  the	  patient	  who	  must	  live	  with	  the	  consequences	  of	  the	  treatment.	  	  If	  a	  patient	  reports	  struggling	  to	  focus	  and,	  after	  being	  thoroughly	  informed	  of	  his	  options,	  believes	  that	  stimulant	  medication	  is	  the	  best	  choice	  for	  him,	  that	  is	  his	  right	  as	  a	  sovereign	  individual.	  	  A	  patient	  should	  not	  be	  denied	  access	  to	  a	  potentially	  beneficial	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substance	  unless	  it	  is	  clear	  that	  the	  substance	  could	  have	  serious	  negative	  effects	  on	  the	  individual.	  	   Beneficence	  is	  the	  most	  intuitive	  principle.	  	  It	  should	  be	  the	  goal	  of	  all	  healthcare	  providers	  to	  relieve	  suffering	  and	  improve	  quality	  of	  life	  in	  everyone	  they	  treat.	  	  If	  a	  patient	  says	  that	  he	  struggles	  consistently	  to	  focus	  on	  important	  tasks	  and	  is	  clearly	  experiencing	  distress,	  it	  is	  the	  duty	  of	  the	  doctor	  to	  combat	  his	  symptoms	  and	  relieve	  his	  distress.	  	  No	  individual	  should	  be	  prohibited	  from	  improving	  his	  quality	  of	  life,	  even	  in	  the	  improvement	  seems	  superficial	  or	  unnecessary	  to	  some.	  	  This	  extends	  to	  all	  those	  who	  feel	  the	  negative	  effects	  of	  attentional	  deficit	  and	  find	  relief	  with	  stimulant	  medication.	  	  Though	  treatment	  for	  ADHD	  symptoms	  comes	  in	  many	  forms—stimulant	  medication,	  CBT,	  meditation—no	  matter	  what,	  the	  doctor	  must	  do	  his	  utmost	  for	  the	  benefit	  of	  the	  patient.	  	  This	  means	  doing	  the	  most	  good	  for	  the	  patient	  while	  respecting	  the	  patient’s	  autonomy.	  	  If	  a	  patient	  wants	  to	  try	  stimulant	  medications,	  the	  doctor	  must	  consider	  the	  pros	  and	  cons	  of	  stimulant	  treatment	  for	  that	  patient.	  	  If	  the	  doctor	  concludes,	  in	  spite	  of	  the	  potential	  risks	  and	  side	  effects,	  that	  stimulant	  treatment	  could	  improve	  the	  patient’s	  condition,	  then	  he	  is	  obligated	  by	  the	  principles	  of	  Beneficence	  and	  Autonomy	  to	  provide	  the	  stimulant	  treatment	  to	  that	  patient.	  	   Nonmaleficence	  is	  the	  big	  no-­‐no	  of	  Principlism,	  and	  in	  a	  way	  it	  is	  the	  mirror	  image	  of	  Beneficence.	  	  Just	  as	  doctors	  should	  seek	  to	  do	  the	  most	  good,	  so	  also	  should	  they	  seek	  to	  do	  the	  least	  harm.	  	  This	  principle	  is	  probably	  the	  least	  relevant	  to	  our	  discussion	  of	  prescription	  stimulants,	  however	  it	  does	  have	  its	  place.	  	  Consider,	  for	  instance,	  a	  patient	  with	  a	  history	  of	  heart	  trouble	  and	  drug	  addiction	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who	  presents	  with	  attention	  deficit	  symptoms	  and	  wants	  to	  try	  stimulant	  medications.	  	  A	  judicious	  doctor	  will	  consider	  the	  risk	  factors	  for	  stimulant	  treatment	  along	  with	  the	  patient’s	  medical	  history	  in	  order	  to	  weigh	  the	  potential	  good	  against	  the	  potential	  harm.	  	  Stimulant	  medications	  can	  cause	  increased	  blood	  pressure,	  increased	  heart	  rate,	  and	  general	  coronary	  distress,	  and	  this	  patient	  has	  a	  history	  of	  heart	  trouble.	  	  Additionally,	  stimulant	  medications	  have	  potential	  for	  abuse,	  and	  this	  patient	  has	  a	  history	  of	  drug	  addiction.	  	  Given	  these	  circumstances,	  it	  is	  clear	  that	  prescribing	  stimulants	  to	  this	  patient	  poses	  considerable	  risk.	  	  They	  could	  exacerbate	  his	  addictive	  tendencies	  and	  possibly	  cause	  his	  heart	  to	  fail.	  	  With	  such	  high	  potential	  for	  harm,	  it	  would	  be	  horribly	  negligent	  to	  prescribe	  stimulants	  to	  this	  patient.	  	  Nonmaleficence,	  in	  this	  case,	  obligates	  the	  doctor	  not	  to	  prescribe,	  and	  to	  instead	  pursue	  safer	  alternatives	  to	  stimulant	  medications.	  	   Justice	  is	  the	  principle	  that	  focuses	  more	  on	  the	  population	  than	  the	  individual,	  as	  it	  demands	  that	  all	  individuals	  should	  have	  equal	  access	  to	  healthcare.	  	  More	  specifically,	  it	  dictates	  that	  benefits	  and	  burdens	  be	  equitably	  distributed	  to	  all.	  	  When	  it	  comes	  to	  stimulant	  medications,	  this	  principle	  comes	  into	  play	  when	  we	  consider	  how	  to	  determine	  who	  should	  have	  them	  and	  who	  shouldn’t.	  	  Under	  the	  current	  paradigm,	  the	  line	  separating	  those	  who	  need	  stimulant	  medications	  and	  those	  who	  do	  not	  is	  ambiguous	  at	  best,	  and	  it	  can	  be	  nearly	  impossible	  to	  determine	  who	  truly	  “needs”	  stimulant	  treatment.	  	  This	  has	  created	  a	  scenario	  where	  many	  people	  who	  might	  not	  meet	  the	  full	  qualifications	  for	  ADHD	  are	  denied	  access	  to	  stimulants,	  while	  others	  who	  may	  not	  even	  be	  noticeably	  different	  are	  granted	  prescriptions.	  	  This	  problematic	  system	  has	  created	  an	  unjust	  distribution	  of	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stimulant	  medications,	  leading	  inevitably	  to	  the	  controversial	  rise	  of	  illicit	  stimulant	  use	  that	  we	  have	  been	  discussing.	  	  Perhaps,	  rather	  than	  determining	  who	  needs	  stimulant	  treatment,	  doctors	  should	  focus	  on	  determining	  who	  could	  benefit	  from	  it.	  	  If	  this	  becomes	  the	  standard,	  perhaps	  more	  people	  will	  be	  helped,	  and	  perhaps	  the	  underground	  redistribution	  of	  benefits	  will	  dissipate	  into	  obsolescence.	  	   Now	  that	  we	  have	  discussed	  the	  role	  of	  each	  principle	  in	  the	  subject	  at	  hand,	  we	  can	  combine	  them	  to	  hopefully	  reach	  a	  defensible	  conclusion.	  	  Beneficence	  dictates	  that	  anyone	  whose	  quality	  of	  life	  can	  be	  increased	  by	  stimulant	  treatment	  should	  be	  able	  to	  get	  it,	  and	  Nonmaleficence	  dictates	  that	  anyone	  whose	  quality	  of	  life	  will	  be	  decreased	  by	  stimulant	  treatment	  should	  not	  be	  given	  it.	  	  Autonomy	  dictates	  that	  each	  individual	  has	  the	  right	  to	  self-­‐determination,	  however	  this	  self-­‐determination	  is	  restricted	  to	  the	  bounds	  of	  Beneficence	  and	  Nonmaleficence.	  	  This	  interplay	  of	  principles	  has	  three	  important	  implications:	  (1)	  an	  individual	  who	  wants	  to	  undergo	  stimulant	  treatment	  and	  stands	  to	  benefit	  from	  it	  despite	  the	  risks	  should	  receive	  stimulant	  treatment;	  (2)	  an	  individual	  who	  wants	  to	  undergo	  stimulant	  treatment	  but	  is	  at	  considerable	  risk	  for	  adverse	  affects	  should	  not	  receive	  stimulant	  treatment;	  (3)	  an	  individual	  who	  does	  not	  want	  to	  undergo	  stimulant	  treatment	  should	  not	  be	  made	  to	  do	  so	  for	  any	  reason.	  	  Finally,	  Justice	  dictates	  that	  all	  people	  should	  have	  equal	  opportunity	  for	  stimulant	  treatment—that	  all	  who	  might	  benefit	  should	  have	  the	  chance	  to	  choose	  for	  themselves.	  	  	  	   Now	  that	  the	  Principlist	  stance	  on	  stimulant	  treatment	  has	  been	  defined,	  we	  can	  compare	  it	  to	  the	  approaches	  we’ve	  discussed.	  	  The	  idea	  of	  prohibiting	  stimulant	  treatment	  across	  the	  board	  is	  clearly	  not	  compatible	  with	  Principlism,	  however	  it	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does	  satisfy	  the	  criteria	  for	  Nonmaleficence	  and	  Justice.	  	  If	  they	  are	  completely	  eliminated,	  stimulant	  medications	  cannot	  do	  harm	  to	  anyone,	  and,	  paradoxically,	  no	  distribution	  is	  equal	  distribution.	  	  Still,	  prohibition	  completely	  ignores	  the	  principles	  of	  Autonomy	  and	  Beneficence.	  	  Individuals	  are	  not	  given	  the	  opportunity	  to	  decide	  what	  they	  want	  for	  themselves,	  and	  those	  who	  might	  find	  stimulant	  treatment	  functionally	  and	  emotionally	  beneficial	  are	  denied	  access	  to	  it.	  	  Though	  it	  errs	  on	  the	  side	  of	  safety	  and	  equality,	  a	  prohibitive	  approach	  that	  precludes	  self-­‐determination	  and	  ignores	  suffering	  is	  ethically	  unsound	  and	  should	  be	  avoided.	  	   	  The	  current	  paradigm	  is	  still	  prohibitive	  in	  nature,	  but	  it	  makes	  concessions	  for	  the	  sake	  of	  Beneficence.	  	  This	  disease	  model	  allows	  stimulant	  medications	  to	  be	  prescribed	  to	  those	  who	  are	  diagnosed	  with	  ADHD,	  but	  essentially	  no	  one	  else.	  	  Ultimately,	  the	  problem	  that	  arises	  is	  with	  the	  principle	  of	  Justice.	  	  Those	  who	  are	  diagnosed	  with	  ADHD	  are	  granted	  the	  autonomy	  to	  refuse	  certain	  treatments	  and	  choose	  the	  one	  they	  prefer,	  however	  the	  criteria	  for	  diagnosis	  can	  be	  very	  ambiguous.	  	  This	  can	  result	  in	  other	  people	  who	  might	  benefit	  from	  stimulant	  treatment	  being	  denied	  access	  to	  it.	  	  The	  basis	  of	  ADHD	  diagnosis	  ultimately	  leads	  to	  an	  unjust	  distribution	  of	  Autonomy	  and	  Beneficence.	  	  Only	  those	  with	  diagnoses	  are	  afforded	  the	  Autonomy	  and	  Beneficence	  they	  deserve,	  while	  those	  who	  are	  not	  diagnosed	  are	  excluded	  from	  any	  choice	  and	  potential	  benefits.	  	  It	  is	  this	  violation	  of	  Justice	  that	  has	  led	  to	  the	  widespread	  illicit	  use	  of	  prescription	  stimulants	  for	  their	  beneficial	  effects.	  	  Though	  not	  as	  heartless	  as	  the	  prohibitive	  approach,	  this	  method	  is	  clearly	  flawed	  and	  therefore	  in	  need	  of	  reform.	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   The	  completely	  unrestrictive	  approach	  from	  the	  case	  for	  enhancement	  is	  satisfying	  for	  all	  but	  one	  of	  these	  principles.	  	  It	  seeks	  to	  provide	  benefit	  for	  all	  who	  will	  have	  it,	  it	  gives	  everyone	  the	  right	  to	  choose	  for	  themselves,	  and	  it	  ensures	  that	  all	  people	  have	  equal	  opportunity	  for	  stimulant	  treatment—Beneficence,	  Autonomy,	  Justice.	  	  However,	  it	  falls	  short	  of	  Nonmaleficence.	  	  As	  exampled	  previously,	  there	  are	  certainly	  people	  who	  should	  not	  be	  prescribed	  stimulants	  due	  to	  increased	  health	  risks.	  	  These	  people	  have	  conditions	  or	  complications	  that	  make	  taking	  stimulants	  very	  dangerous,	  and	  many	  could	  be	  at	  risk	  for	  harmful,	  even	  life-­‐threatening	  effects.	  	  An	  approach	  that	  hands	  out	  stimulant	  medications	  to	  anyone	  and	  everyone	  is	  woefully	  irresponsible,	  and	  therefore	  not	  advisable.	  	   Ultimately,	  the	  ideal	  ethical	  approach	  seems	  to	  fall	  somewhere	  between	  the	  current	  method	  and	  the	  free-­‐for-­‐all	  method.	  	  Instead	  of	  qualifying	  people	  based	  on	  need	  and	  creating	  arbitrary	  restrictions,	  we	  should	  qualify	  them	  based	  on	  potential	  for	  benefit.	  	  This	  would	  allow	  for	  a	  more	  equitable	  access	  and	  increased	  self-­‐determination.	  	  Conversely,	  instead	  of	  giving	  everyone	  the	  choice	  to	  use	  or	  not	  use	  stimulants,	  we	  should	  only	  give	  it	  to	  those	  whose	  potential	  benefits	  outweigh	  their	  potential	  risks.	  	  In	  this	  way,	  Nonmaleficence	  is	  not	  overlooked.	  	  I	  believe	  this	  ethical	  approach	  would	  provide	  an	  appropriate	  level	  of	  control	  while	  allowing	  for	  maximization	  of	  benefits	  and	  free	  individual	  choice.	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